Butyrate

PubMed ID: 38871078

Metformin users showed enrichment of butanoate metabolism pathways in microbiome analyses—associative human cohort evidence linking drugs, microbiome and butyrate pathways.

PubMed ID: 31688306

UC subgroup analysis measured fecal SCFAs and butyrate changes linked to disease activity and treatment.

PubMed ID: 25016597

Crossover diet RCT showed diet markedly changes abundance of butyrate‑producing taxa (Clostridium cluster XIVa) — strong evidence linking diet/microbiota to butyrate producers.

PubMed ID: 32675291

Probiotic including butyrate producers changed stool butyrate trends and clinical glycemic outcomes — supports beneficial microbiota modulation.

PubMed ID: 34956218

Randomized oat intervention increased beneficial microbes including Akkermansia and Roseburia (butyrate‑associated)—strong human RCT evidence for shifting toward butyrate‑friendly microbiome.

PubMed ID: 34996347

Probiotic RCT increased circulating butyrate and altered bile acids; direct human evidence of microbiome modulation raising butyrate.

PubMed ID: 35521810

Prebiotic‑rich brown yogurt increased Akkermansia, Ruminococcus and Faecalibacterium—human RCT evidence for increasing butyrate‑associated taxa.

PubMed ID: 33188417

Whole‑grain wheat increased microbiota‑predicted butyrate fermentation pathways and altered Ruminococcaceae genera.

PubMed ID: 15080850

Direct evidence: lactulose increased faecal bifidobacteria; PEG decreased fecal butyrate — clear microbiota/SCFA findings relevant to balance.

PubMed ID: 17623227

Human trial: daily lactitol significantly increased bifidobacteria and fecal butyrate — direct evidence of microbiota modulation linked to butyrate.

PubMed ID: 31686768

Prebiotic increased abundance of Roseburia hominis, a known butyrate producer—direct evidence for shifting gut microbial composition toward butyrate producers.

PubMed ID: 37821689

Personalized GI nutrition produced a clear increase in fecal butyrate—strongest direct human signal in this set for modulating gut microbial metabolism.

PubMed ID: 39864520

Inulin (a prebiotic) altered fecal metabolome and linked taxa with host markers; inulin fermentation commonly promotes butyrate-producing bacteria.

PubMed ID: 31848609

Walnut diets increased known butyrate‑producing genera (Roseburia, Eubacterium) and linked those taxa to clinical improvements.

PubMed ID: 35411007

Omega‑3/ALA oils boosted butyrate‑associated Clostridia abundances and microbial diversity — clear shift toward butyrate‑producer enrichment.

PubMed ID: 39189588

Postbiotic pill increased fecal butyrate and enriched butyrate‑producing taxa (Faecalibacterium) — direct microbiome evidence.

PubMed ID: 40263513

Randomized double‑blind trial showed increases in SCFA/butyrate‑producing taxa with casein hydrolysate and activation of butyrate pathways.

PubMed ID: 39033197

Inulin supplementation in children increased abundance of several butyrate‑producing genera (Agathobacter, Subdoligranulum) and alpha diversity.

PubMed ID: 32330237

Infant feeding strongly altered fecal microbiota and butyrate levels (observational human cohort showing diet‑driven balance differences).

PubMed ID: 29470389

Randomized walnut intervention increased butyrate‑producing and probiotic taxa in humans—strong evidence dietary change can boost butyrate producers (microbiome RCT).

PubMed ID: 33167908

Direct evidence: infant feeding with extensively‑hydrolyzed formula increased butyrate‑producing bacteria and stool butyrate vs human milk — strong direct microbiome/SCFA data.

PubMed ID: 8164297

Human fiber intervention substantially increased butyrate — indicates altered fermentation favoring butyrogenic activity and a more balanced SCFA profile (indirect evidence).

PubMed ID: 7654893

Direct clinical improvement in distal UC with SCFA enemas supports trophic/repair effects on colonic mucosa.

PubMed ID: 9706795

Fermented oats increased fecal SCFA and raised fecal lactobacilli counts—direct evidence of beneficial microbiota changes.

PubMed ID: 9440384

Fermented milks increased beneficial bacteria and reduced harmful bacterial enzyme activities in infants (microbiome-modulating effects), though no fecal SCFA change was observed.

PubMed ID: 10022641

Oral fiber (Plantago ovata) increased fecal butyrate, indicating altered microbial fermentation and a shift in microbiota metabolic output.

PubMed ID: 12038477

Fine wheat bran increased colonic fermentation and fecal butyrate output—acts via microbiota fermentation and thus supports modulation of gut microbial metabolic activity (indirect marker of community function).

PubMed ID: 10795763

Direct oral sodium butyrate improved histologic scores in UC, indicating support for the gut lining.

PubMed ID: 11053512

Acarbose increased fecal butyrate and rectal crypt BrdU uptake (mucosal proliferation), supporting direct gut lining effects.

PubMed ID: 12641543

Direct clinical and endoscopic/histologic improvements in distal UC after topical butyrate indicate mucosal (gut lining) healing and support.

PubMed ID: 16469156

Lupin fibre raised faecal butyrate in humans; butyrate is a primary energy source for colonocytes and supports mucosal health — this supplies moderate human evidence for gut‑lining support (indirect via fiber intervention).

PubMed ID: 18689571

Directly relevant: prebiotic resistant maltodextrin increased fermentative bacteria and shifted stool SCFA composition toward higher butyrate, supporting an effect on gut microbial balance.

PubMed ID: 20018483

Infant formula with Lactobacillus salivarius raised fecal lactobacilli and increased fecal butyrate—direct evidence linking intervention to microbiota and butyrate changes.

PubMed ID: 20089780

Rye raised fecal butyrate substantially — supports colonocyte energy and mucosa.

PubMed ID: 20799286

Mechanical bowel prep reduced Bifidobacterium/Lactobacillus and faecal butyrate — clear human evidence that interventions change beneficial taxa and SCFAs.

PubMed ID: 20580604

Probiotic fermented milk increased stool butyrate—directly ties probiotic intervention to SCFA profile and suggests modulation of gut microbiota function.

PubMed ID: 21430242

Resistant‑starch feeding in humans usually raised fecal butyrate and total SCFA; resistant starch is known to favor butyrate‑producing microbes—good indirect microbiota support.

PubMed ID: 21910949

Human trial: GOS increased bifidobacteria and raised butyrate in an in vitro proximal-colon model — direct evidence that prebiotic interventions can shift bacteria toward a butyrogenic, more balanced profile.

PubMed ID: 22574737

Human RCT showed accelerated rectal epithelial histologic healing and increased epithelial antimicrobial-peptide expression after sodium-butyrate enemas—direct evidence for supporting the gut lining.

PubMed ID: 22743314

Inulin increased bifidobacteria and altered fecal pH/lactate—evidence of prebiotic-induced microbial balance shifts.

PubMed ID: 22264499

Reduction in circulating LPS (endotoxaemia) with INU+XOS implies improved gut barrier function or reduced translocation.

PubMed ID: 22657950

AXOS treatment increased fecal bifidobacteria and total bacteria and raised butyrate—clear microbiota modulation.

PubMed ID: 24063909

Traveler RCT: oral sodium butyrate/SCFA markedly reduced diarrhoea incidence and stool frequency, implying preserved barrier/function under enteric challenge (human RCT).

PubMed ID: 23957631

Synbiotic RCT in older adults raised bifidobacterial numbers and increased butyrate production — direct evidence for microbiota modulation (human RCT).

PubMed ID: 24343275

Clinical reduction in diverticulitis and symptom improvement suggest positive effects on colonic mucosa.

PubMed ID: 24385355

Randomized trial: Lactobacillus paracasei LC01 increased beneficial bacteria (Lactobacillus, Bifidobacterium), raised fecal SCFAs (including butyrate) and lowered E. coli.

PubMed ID: 23977723

Butyrylated starch in humans substantially increased fecal free and bound butyrate and strongly increased specific beneficial taxa (P. distasonis, F. prausnitzii).

PubMed ID: 23776267

Whole‑wheat diluted turkey diets raised cecal butyric acid and increased beneficial bacteria while lowering Salmonella (animal evidence of microbiota benefits).

PubMed ID: 24933989

Study explicitly reported improved gut microbiota profiles after oral butyrate+inulin supplementation in patients.

PubMed ID: 24671237

GOS prebiotic changed bifidobacteria counts and SCFA profile (including decreased relative butyrate%) in infants—direct microbiota/SCFA modulation evidence.

PubMed ID: 25207431

Animal data: butyric acid glycerides reduced gut lesions, consistent with support for the mucosal lining.

PubMed ID: 24642201

Pistachio consumption shifted microbiota toward more butyrate‑producing taxa in a short feeding trial, indicating positive modulation of bacterial balance.

PubMed ID: 26556275

Single antibiotic courses substantially and durably disturbed the fecal microbiome and reduced predicted butyrate-producing pathways—strong evidence that butyrate producers are central to a balanced gut microbiota (human data).

PubMed ID: 25726104

Direct sodium-butyrate supplementation in ruminants promoted rumen papillae and muscular development—strong animal-model evidence for structural support of the gut lining.

PubMed ID: 25817063

Administration of M. elsdenii increased ruminal butyrate and altered rumen development—shows microbiome interventions can raise butyrate and change community function (animal model).

PubMed ID: 27411009

Vancomycin drastically altered gut bacterial diversity and reduced Firmicutes involved in SCFA (including butyrate) metabolism — direct evidence that SCFA pathways and gut bacteria are linked in humans.

PubMed ID: 27528065

Observational data showing lower abundance/capacity of butyrate-producing bacteria in obese pregnant women, linking butyrate-producer deficits to adverse phenotypes.

PubMed ID: 28000678

Prebiotic supplementation increased Faecalibacterium and Lachnospira (butyrate producers) and raised butyrate — direct evidence of shifting toward a more butyrogenic microbiota.

PubMed ID: 27548249

Therapeutic iron + vitamin E increased abundance of Roseburia (a butyrate-producer) in iron-deficient infants — direct change in butyrate-producing bacterial population (human).

PubMed ID: 26907339

Human dietary study showed trends to altered fecal SCFAs (including butyrate) alongside changes in metabolome — supports microbiota/metabolic shifts.

PubMed ID: 27097436

Broiler diet/lighting changes shifted fecal microbiota and SCFA profiles (incl. butyrate) — animal evidence of microbiota modulation.

PubMed ID: 28214040

Arabinoxylan fiber significantly increased fecal total SCFAs including butyrate, indicating enhanced fermentative activity by gut microbes.

PubMed ID: 28410921

Randomized resistant starch increased Bifidobacterium and reduced Proteobacteria dysbiosis in elderly participants while raising stool butyrate—direct microbiome evidence.

PubMed ID: 28179226

Whole-grain diet changed microbiota composition (some taxa shifts) and raised stool SCFAs, linking diet-driven microbiome modulation to SCFA changes.

PubMed ID: 28063242

Animal data show butyrate improved villus height/absorptive cell area and reduced endotoxin—strong evidence for support of gut lining (animal model).

PubMed ID: 28077379

Resistant starch/polydextrose altered rectal mucosa gene expression (notably SFRP1, β‑catenin, c‑MYC), indicating an effect on mucosal biology consistent with butyrate's actions on the epithelium.

PubMed ID: 30716942

Synbiotic intervention raised fecal butyrate and decreased fecal pH, indicating altered microbial fermentation; direct microbiome data not detailed in summary but changes in SCFA are strong evidence of microbiota modulation.

PubMed ID: 30145102

Study documents loss of butyrate‑producing taxa after eradication and shows that C. butyricum supplementation increases that organism and helps restore microbiota — strong direct human evidence for re‑balancing butyrate producers.

PubMed ID: 31797399

Randomized probiotic trial increased Bifidobacterium and fecal butyrate — direct evidence for shifting gut microbiota toward beneficial taxa.

PubMed ID: 30940833

Randomized dose‑response trial showed FOS increased alpha-diversity, bifidobacteria, and several butyrate-producing taxa — direct evidence of a shift toward a more 'balanced' microbiome and increased butyrate producers.

PubMed ID: 30897686

Daily oral E. coli-targeting phages reduced E. coli abundance (~40%) in responders and changed microbiome composition, demonstrating targeted modulation of gut bacteria.

PubMed ID: 32075887

Mediterranean diet intervention increased some butyrate-producing taxa (e.g., Faecalibacterium) in subsets of participants, indicating diet-driven beneficial microbiome shifts.

PubMed ID: 32476236

Oral microencapsulated sodium butyrate produced a significant shift toward butyrogenic/SCFA-producing genera (PERMANOVA p=0.045) in UC — direct support for balancing gut bacteria.

PubMed ID: 33388204

Polyphenol diet enriched fibre‑fermenting and butyrate‑producing taxa (Ruminococcaceae, Faecalibacterium).

PubMed ID: 33243018

Quxie capsule altered microbiome composition, increasing SCFA‑producing taxa associated with higher CD4+ counts.

PubMed ID: 32660025

Zonulin reduction with raised plasma butyrate suggests improved mucosal barrier.

PubMed ID: 33444970

Almond intake produced significant shifts in fecal microbiota composition and increased diversity (Ruminococcaceae increases) despite no fecal SCFA rise.

PubMed ID: 32564657

Strong association: postoperative cluster enriched for butyrate-producing Lachnospiraceae predicted lower Crohn recurrence.

PubMed ID: 32536582

Short‑term overfeeding study reported increases in butyrate‑producing taxa with unsaturated‑fat overfeeding, showing modulation of butyrate producers.

PubMed ID: 33785557

Repeated FMT produced strong donor microbiota engraftment.

PubMed ID: 33567701

Synbiotic increased Bifidobacterium/Lactobacillus and fecal butyrate.

PubMed ID: 33505154

L. plantarum changed microbiota composition despite no fecal butyrate change.

PubMed ID: 34365905

Large RCT in lactose-intolerant adults where GOS robustly increased bifidobacteria and several butyrate-associated taxa (direct evidence of balancing).

PubMed ID: 34534897

Polyphenol diet decreased zonulin (marker of permeability) and correlated with increased butyrate-producers — strong support for lining integrity.

PubMed ID: 33382352

Inulin supplementation raised circulating butyrate and shifted specific butyrate-associated genera (human RCT evidence).

PubMed ID: 33671147

RS2‑enriched wheat enriched butyrate‑associated taxa (Ruminococcus, Roseburia, Faecalibacterium) within 1 week, indicating microbiome shifts toward butyrate producers.

PubMed ID: 34523948

Human dietary intervention increased abundance of butyrate-producing taxa alongside clinical changes — supports link between microbiome composition (butyrate producers) and host outcomes.

PubMed ID: 33530034

Human observational: reduced Coprococcus (a butyrate producer) associated with later preeclampsia — strong human evidence that loss of butyrate-producers marks dysbiosis with clinical consequences.

PubMed ID: 36055959

Mediterranean diet increased fecal butyrate and improved markers of intestinal permeability — direct human evidence linking SCFA increases to gut lining support.

PubMed ID: 36003050

LGG probiotic increased fecal butyrate in infants with colic/eczema and associated clinical improvements, indicating beneficial microbiome modulation.

PubMed ID: 35079761

B. bifidum increased fecal butyrate and improved constipation—microbiome modulation consistent with balanced gut bacteria.

PubMed ID: 36228567

Aronia polyphenols increased gene richness and abundance of butyrate‑producing species (direct microbiome evidence).

PubMed ID: 36717369

Probiotic increased abundance of SCFA producers (Butyricimonas, etc.) and fecal butyrate in IBS‑D patients.

PubMed ID: 35102419

High‑resistant‑starch wheat RCT increased fecal butyrate and Roseburia (butyrate‑producer), evidence for microbiota balancing.

PubMed ID: 36517799

Prebiotic significantly increased serum butyrate and raised Bifidobacterium adolescentis, Lactobacillus—direct microbiota balancing.

PubMed ID: 35833889

Germinated brown rice increased stool SCFAs and Bacteroides abundance—microbiome shifts toward beneficial taxa.

PubMed ID: 35029612

Increase in butyrate‑producing genera in celiac patients associated with improved intestinal morphology/microbial balance.

PubMed ID: 36067589

Nighttime peanut snack increased Ruminococcaceae and expression of butyrate‑pathway genes (metatranscriptomics).

PubMed ID: 35185013

Probiotic supplementation in preterm infants raised fecal SCFAs including butyrate (microbial balance effect).

PubMed ID: 36499011

Fecal butyrate increases and stool improvements imply enhanced mucosal/lining health.

PubMed ID: 35500381

Fermented brown rice increased abundance of several butyrate‑producing taxa and SCFA production in metabolic syndrome.

PubMed ID: 35268024

Probiotic gummy significantly increased fecal butyrate and boosted relative abundance of known butyrate-producing genera.

PubMed ID: 36811568

Synbiotic infant formula produced microbiota shifts (↑Bifidobacterium, ↑Lactobacillaceae) resembling breastfed profiles—evidence of microbiome balancing (even though fecal butyrate fell).

PubMed ID: 35938351

Probiotic-enriched diet increased beneficial bacteria (Lactobacilli/Bifidobacteria) and raised fecal butyrate in older adults.

PubMed ID: 37451270

RCT FMT improved gut barrier integrity markers alongside increases in butyrate‑producing bacteria.

PubMed ID: 36678227

Probiotic use in CRC patients increased microbiota diversity and raised fecal SCFAs including butyrate.

PubMed ID: 37367942

Observational link between A. hadrus counts and higher fecal butyrate and better clinical outcomes in chemo patients.

PubMed ID: 36594522

Prebiotic fibre increased abundance of butyrate‑producing taxa (Roseburia, Anaerostipes) in T2D RCT.

PubMed ID: 37751049

GOS intake greatly increased bifidobacteria/lactobacilli and fecal/plasma butyrate — clear prebiotic effect on microbiota balance.

PubMed ID: 37898434

Wholegrain oats/rye modulated gut microbiota and increased fecal/plasma SCFAs including butyrate.

PubMed ID: 37111201

Synbiotic (SIM01) restored beneficial microbes (e.g., Bifidobacterium) and altered microbiome composition significantly.

PubMed ID: 37940573

Black tea increased certain gut taxa, including some butyrate‑producers, in specific subgroups.

PubMed ID: 38135194

Direct evidence: 12 weeks of oral butyrate reduced plasma zonulin, a validated marker of intestinal permeability.

PubMed ID: 36856122

Agave fructans + L. casei increased SCFAs including butyrate and altered microbiota markers in overweight children.

PubMed ID: 37441828

Dose‑dependent increase in fecal SCFAs including butyrate following multispecies probiotic—evidence of modulating gut microbial fermentation.

PubMed ID: 38717445

B. longum NCC3001 increased plasma butyrate and altered mood and amygdala responses—shows probiotic can raise butyrate systemically (microbiome effect).

PubMed ID: 39003477

Sodium‑butyrate RCT in UC produced significant reductions in fecal calprotectin and upregulated mucosal clock genes—strong evidence for mucosal support.

PubMed ID: 39689011

taVNS increased fecal SCFAs and Bifidobacterium abundance—intervention shifted microbiota/metabolome.

PubMed ID: 38732615

Significant zonulin reduction (marker of intestinal permeability) after multi‑ingredient supplement including butyrate—direct evidence for gut lining support, though combined formula limits attribution.

PubMed ID: 39599737

Heat‑treated B. longum significantly increased abundance of multiple butyrate‑producing taxa and transiently increased total SCFAs—strong evidence for rebalancing toward butyrate producers.

PubMed ID: 39599626

Multispecies probiotic increased microbial richness and stool butyrate over months—clear support for beneficial microbiome modulation.

PubMed ID: 38865630

Combined rifaximin+probiotic+prebiotic increased stool SCFAs including butyrate and altered microbiota toward more favorable taxa—supports microbiome rebalancing.

PubMed ID: 39064648

Dietary‑fiber/postbiotic increased putative butyrate‑producing taxa (Eubacterium eligens, Anaerostipes) with metabolic benefits—strong support for microbiota balance.

PubMed ID: 39438902

Oral FMT from butyrate‑rich donors engrafted butyrate‑producing taxa (Lachnospiraceae, Ruminococcaceae), showing robust microbiome reshaping toward butyrate producers.

PubMed ID: 38315140

Colon‑targeted rifamycin changed stool SCFA profile (increasing butyrate) and altered gut metabolism—consistent with microbiome modulation.

PubMed ID: 38631185

Multi‑species synbiotic increased stool SCFAs (including butyrate) — direct intervention to rebalance gut bacteria/SCFAs.

PubMed ID: 38776887

Probiotic add‑on increased stool butyrate and altered gene expression, consistent with beneficial microbiome shifts.

PubMed ID: 39631208

Large dietary RCT showed that minimally processed carbohydrates increased fecal butyrate while LCHF reduced SCFAs — demonstrates diet‑driven microbiome/SCFA balance.

PubMed ID: 38957464

Probiotic H. coagulans increased fecal butyrate significantly vs placebo—evidence of a favorable microbiome/metabolic shift associated with butyrate production.

PubMed ID: 38684660

12‑week multi‑species synbiotic raised stool SCFAs including butyrate and altered miRNA/lipid markers, indicating microbiome modulation.

PubMed ID: 39963956

Micronutrient trial increased abundance of butyrate‑producing families in clinical responders, showing community shifts toward butyrate producers.

PubMed ID: 40286792

Postbiotic intervention altered fecal metabolites (butyrate) alongside clinical benefit, supporting ecosystem/functional change.

PubMed ID: 40669445

Chicory fiber increased fecal SCFAs (including butyrate) indicating a shift in microbial fermentation patterns.

PubMed ID: 40369689

Infant formula altered microbiota to favor Ruminococcaceae/Lachnospiraceae and increased fecal butyrate.

PubMed ID: 40575487

Probiotic increased tight‑junction protein (occludin) and reduced L/M ratio while raising butyrate—direct gut‑lining support.

PubMed ID: 40635319

Calcium butyrate treatment produced shifts toward SCFA‑producing taxa in children with IBS.

PubMed ID: 40167641

Sodium butyrate decreased zonulin (marker of gut‑lumen barrier integrity) and endotoxin exposure markers.

PubMed ID: 40366770

Randomized probiotic+inulin increased fecal SCFAs and enriched microbiome genes tied to SCFA production, shifting community function.

PubMed ID: 40371708

Oral Anaerobutyricum increased fecal carriage of the strain, reflecting a shift in butyrate‑producing community members.

PubMed ID: 41233756

Inulin promoted growth of butyrate‑producing genera (Anaerostipes, Coprococcus) linked to a healthier microbial balance.

PubMed ID: 40274191

High‑dose inulin boosted butyrate production and plasma levels, which are known to nourish colonocytes and support barrier integrity.

PubMed ID: 40577952

Oral butyrate (16 weeks) lowered plasma zonulin and LBP (markers of intestinal permeability), supporting tighter barrier function.

PubMed ID: 41422374

Butyrate increased fecal C4 and improved UC mucosal/endoscopic outcomes, indicating direct mucosal support.

PubMed ID: 40081693

Butyrate supplementation decreased zonulin and LBP — direct biomarkers of improved gut barrier/integrity.

PubMed ID: 41354580

Improvements in IBD activity and fecal calprotectin suggest mucosal healing and lining support.

PubMed ID: 40182598

Probiotic drink RCT raised stool butyrate and increased Bifidobacterium and altered microbiota composition—directly supports microbiota balance.

PubMed ID: 41327655

Lowered serum D‑lactate and increased stool butyrate after treatment suggest improved mucosal barrier/lining (indirect).

PubMed ID: 40751371

FMT produced durable increases in fecal butyrate that correlated with symptom benefit and sustained microbiome changes—strong evidence for microbial balance effects.

PubMed ID: 40421856

Prebiotic intervention increased fecal butyrate alongside other improvements, consistent with beneficial shifts in microbiota (multi‑component study).

PubMed ID: 39153842

Probiotic (live or heat‑inactivated) in preterm infants increased fecal butyrate and altered microbiota — supports microbiota modulation.

PubMed ID: 40947861

Butyrylated starch increased fecal butyrate and changed colonic environment (pH), consistent with promoting butyrate‑producing activity.

PubMed ID: 41197269

Probiotic increased fecal SCFA (including butyrate) and shifted gut microbes in children—supports rebalancing toward SCFA producers.

PubMed ID: 40670166

Acupuncture increased abundance of butyrate‑producing taxa in MCI patients—supports microbiome shifts favoring butyrate producers (indirect clinical relevance).

PubMed ID: 41261535

RCT showed increased relative abundance of butyrate producers (Roseburia, Prevotella) after intervention—strong evidence of microbiome balancing toward butyrate producers.

PubMed ID: 40459911

Quadruple H. pylori therapy preserved diversity and butyrate‑producing bacteria better than triple therapy—evidence that treatment choices affect retention of beneficial taxa.

PubMed ID: 40960896

Baseline microbiome clusters (Faecalibacterium‑dominated) strongly influenced metabolic responses to wholegrain and were linked to butyrate responses—evidence linking community composition to function.

PubMed ID: 41582618

Soy‑protein diet transiently increased fecal butyrate and altered gut bacteria composition.

PubMed ID: 37751049

GOS gummy increased fecal/plasma butyrate and improved constipation and QoL — strong direct improvement in digestion-related outcomes.

PubMed ID: 37898434

Wholegrain diet raised SCFAs and changed microbiota composition with modest metabolic benefits, supporting digestive health.

PubMed ID: 37111201

Synbiotic restored beneficial gut microbes and reduced adverse health outcomes — supports improved gut health/digestion indirectly.

PubMed ID: 36856122

Synbiotic intervention raised fecal butyrate and improved lipid markers in overweight children, suggesting beneficial gut metabolic effects.

PubMed ID: 37441828

Probiotic raised fecal butyrate in obese women and likely supports digestive function via SCFA increases (direct stool measure).

PubMed ID: 39003477

Oral sodium‑butyrate lowered intestinal inflammation (fecal calprotectin) and improved sleep/QoL in UC — direct gut health improvement.

PubMed ID: 39689011

taVNS increased fecal SCFAs (including butyrate) and significantly improved abdominal pain in constipated IBS patients—direct symptomatic benefit.

PubMed ID: 39599737

Heat‑treated B. longum increased faecal butyrate and butyrate‑producing taxa and benefited participants with mild GI symptoms—directly supports digestive health via increased butyrate.

PubMed ID: 38865630

Rifaximin+probiotic+prebiotic raised stool SCFAs and improved gut permeability/inflammation—consistent with healthier digestive milieu (multi‑agent study).

PubMed ID: 38315140

Colon‑targeted rifamycin increased stool SCFAs (including butyrate) and reduced venous ammonia, with small improvements in lean mass/strength—implies improved colonic metabolism and digestion.

PubMed ID: 38631185

Synbiotic increased stool SCFAs including butyrate in dyslipidemic men — supports digestive health through SCFA effects.

PubMed ID: 38931207

Symbiotic meal raised stool SCFAs (incl. butyrate), improved bowel function and lowered some uremic toxins — strong direct digestive benefit.

PubMed ID: 39455612

Preemptive multimodal analgesia group had higher stool butyrate and markedly lower postoperative GI dysfunction — association between butyrate and better GI outcomes.

PubMed ID: 40286792

Postbiotic RCT increased bowel movements and reduced straining while raising fecal butyrate in chronic constipation.

PubMed ID: 40575487

SCFA‑producing probiotic RCT reduced IBS symptom severity and raised fecal butyrate—direct clinical evidence for improved digestion.

PubMed ID: 40635319

Oral calcium butyrate in children with IBS produced large reductions in abdominal pain and high treatment success rates.

PubMed ID: 40366770

B. animalis + inulin increased fecal SCFAs including butyrate and enriched SCFA‑related genes, supporting digestive function.

PubMed ID: 41233756

Inulin (12 g/day) RCT increased stool frequency and improved constipation‑related QoL while promoting butyrate‑linked bacteria.

PubMed ID: 40274191

High‑dose inulin increased butyrate production and fecal/plasma SCFAs — physiological support for colonic health and digestion.

PubMed ID: 41422374

Sodium butyrate supplementation improved clinical and endoscopic indices in UC, reflecting improved gut health and digestion.

PubMed ID: 41354580

Oral butyrate improved clinical disease activity and quality of life in IBD — strong evidence for improved digestive health.

PubMed ID: 40182598

Probiotic drink raised stool butyrate and beneficial taxa, indicating a more favorable gut environment for digestion (indirect).

PubMed ID: 40751371

FMT‑linked increases in fecal butyrate correlated with sustained symptom improvements in IBS (improved digestion/bowel symptoms).

PubMed ID: 25016597

Human crossover showed diet alters butyrate‑producer taxa and fecal pH — directly relevant to colonic fermentation and digestion.

PubMed ID: 34956218

Oat intervention increased SCFAs and butyrate‑producer taxa—direct dietary modulation of gut microbes that support healthy digestion.

PubMed ID: 35521810

Brown/prebiotic‑rich yogurt increased Akkermansia and several butyrate‑associated gut bacteria—strong support for improved gut microbial ecology and digestion.

PubMed ID: 15080850

Directly measured microbiota (bifidobacteria) and fecal butyrate with different laxatives — relevant to fermentation and digestive ecosystem.

PubMed ID: 17623227

Human study (lactitol) increased bifidobacteria and fecal butyrate — reasonably supportive of healthier digestion/microbiota.

PubMed ID: 31686768

Significant improvement in stool frequency in mildly constipated adults indicates clearer benefits for digestion.

PubMed ID: 39189588

Postbiotic pill directly increased fecal butyrate and produced marked clinical improvement in chronic diarrhea — strong evidence for improved digestive health.

PubMed ID: 32330237

Higher fecal butyrate and beneficial microbes in breastfed infants is consistent with healthier digestive ecosystem (observational human data).

PubMed ID: 8164297

Human trial showed substantial butyrate rise with fiber — butyrate promotes colonic health and fermentation balance (indirect clinical relevance).

PubMed ID: 7654893

SCFA enemas improved symptoms (bleeding, urgency) in distal UC — clinical digestive benefit.

PubMed ID: 9706795

Fermented oats increased fecal SCFA (including butyrate), raised lactobacilli and increased stool volume—supporting digestive health.

PubMed ID: 12038477

Wheat bran increased fecal bulk and fecal butyrate output—direct evidence for improved stool properties and colonic fermentation indicative of healthier digestion.

PubMed ID: 12641543

Adding topical butyrate improved bowel symptoms (frequency/urgency) and endoscopic disease — clinically meaningful improvement in digestive health in distal UC.

PubMed ID: 16469156

Human lupin‑fibre trial increased faecal butyrate, stool output and sped transit — direct human evidence of improved bowel/ digestion metrics (strong indirect evidence for butyrate‑mediated digestive benefit).

PubMed ID: 19224658

Human dietary intervention changed faecal butyrate, total SCFA, stool weight and defecation frequency—direct links between SCFA (including butyrate) and digestive outcomes.

PubMed ID: 19480733

Sodium butyrate in piglets improved post‑weaning growth and several digestibility measures—strong animal evidence for improved digestive function.

PubMed ID: 20089780

Whole-grain rye raised fecal butyrate and relieved constipation.

PubMed ID: 20580604

Trial reported increased stool butyric acid and improved stool consistency/defecation frequency—direct evidence for improved digestion/ stool form.

PubMed ID: 22574737

Butyrate enemas improved rectal mucosal healing and reduced local inflammation in shigellosis, indicating improved colonic mucosal health and local digestion-related integrity.

PubMed ID: 22264499

XOS (±INU) raised fecal butyrate and reduced endotoxaemia—supports healthier gut function.

PubMed ID: 22657950

AXOS-enriched bread increased fecal butyrate and increased bifidobacteria—favorable for digestion.

PubMed ID: 24063909

Randomized traveler study: sodium butyrate/SCFA significantly reduced incidence of travellers' diarrhoea, stool frequency and GI symptom scores (human RCT).

PubMed ID: 23957631

Synbiotic increased butyrate production and lowered systemic inflammation, which can support overall digestive health (human RCT).

PubMed ID: 24343275

Randomized placebo-controlled trial: microencapsulated sodium butyrate for 12 months reduced clinical diverticulitis episodes and improved patient-reported digestive symptoms.

PubMed ID: 24385355

Probiotic increased fecal acetate and butyrate and beneficial bacteria while lowering E. coli and ammonia—changes consistent with healthier digestion.

PubMed ID: 22738315

Sodium butyrate added to therapy for IBS patients reduced pain on defecation, urgency and improved bowel habit/frequency—direct symptomatic benefit to digestion.

PubMed ID: 24933989

Clinical improvement in UC/celiac patients with butyrate+inulin (symptoms, microbiota) supports better digestion in diseased gut contexts.

PubMed ID: 25207431

Butyric acid glycerides reduced intestinal lesions and parasite burden and improved growth/performance in broilers—clear digestive benefit in animals.

PubMed ID: 26556275

Antibiotics (esp. clindamycin, ciprofloxacin) reduced butyrate-producing taxa/pathways for months—shows importance of butyrate producers for normal gut function (indirect evidence linking butyrate to healthy digestion).

PubMed ID: 25726104

Sodium-butyrate increased feed intake and rumen tissue development—markers of improved digestive function in ruminants (animal model).

PubMed ID: 25817063

Probiotic-induced increases in ruminal butyrate accompanied better starter intake and greater weaning weight—functional digestive improvements in calves (indirect for butyrate).

PubMed ID: 26015588

Butyric acid supplementation in broilers improved feed conversion and growth, indicating improved digestive efficiency in animals.

PubMed ID: 28000678

Prebiotic increased butyrate-producing taxa and reduced inflammatory/translocation markers, consistent with healthier gut function.

PubMed ID: 27544256

Sodium butyrate lowered Salmonella shedding in pigs and produced small growth/health benefits — direct animal evidence of improved gut health/digestion under challenge.

PubMed ID: 27065265

Swine diets with xylanase improved digestibility and reported higher cecal butyrate — strong animal link between butyrate and digestive efficiency.

PubMed ID: 28214040

Arabinoxylan supplementation raised fecal butyrate and total SCFAs, consistent with enhanced colonic fermentation and digestive fermentation activity.

PubMed ID: 28410921

Resistant starch increased stool butyrate and beneficial Bifidobacterium, indicating improved fermentative digestion and colonic SCFA production.

PubMed ID: 28954842

Whole-grain interventions increased fecal butyrate and modestly increased stool frequency in overweight adults—supports digestive function.

PubMed ID: 28063242

Butyrate supplementation improved intestinal morphology and reduced heat-stress injury in chickens—strong animal evidence for improved gut health.

PubMed ID: 28866384

Infant cohort found lower fecal butyrate precedes eczema (an allergic/atopic outcome), suggesting butyrate production may protect against developing sensitivities (observational).

PubMed ID: 30145102

After H. pylori eradication, C. butyricum supplementation increased that organism and was associated with improved defecatory symptoms — direct human evidence of improved GI function tied to restoring butyrate producers.

PubMed ID: 31797399

Probiotic (B. animalis BB‑12) randomized trial reduced infant colic and increased fecal butyrate — direct clinical evidence of improved digestion/symptoms.

PubMed ID: 32476236

Oral sodium butyrate (60 d) shifted microbiota to more butyrogenic taxa and improved quality-of-life scores in ulcerative colitis patients — a clinical indicator of improved gut symptoms/digestion.

PubMed ID: 40421856

Prebiotic/physical therapy raised fecal butyrate and reduced endotoxin — changes compatible with healthier gut function (indirect, multi‑intervention).

PubMed ID: 40947861

Butyrylated starch increased fecal butyrate and lowered fecal pH in FAP patients, indicating altered colonic fermentation consistent with digestive effects.

PubMed ID: 41261535

In Parkinson's with constipation, acupoint catgut embedding increased fecal SCFAs (including butyrate), raised butyrate‑producers and improved spontaneous bowel movements—direct clinical digestive benefit linked to butyrate increases.

PubMed ID: 32945066

FMT increased fecal butyrate and higher butyrate correlated with reduced IBS symptom severity and fatigue.

PubMed ID: 32564657

Butyrate-producer–enriched postoperative microbiota associated with maintenance of remission—strong link to digestive health.

PubMed ID: 32433273

Clinical IBS trial where low‑FODMAP ± B‑GOS produced substantial symptom relief (despite reduced fecal butyrate), directly relevant to digestive symptoms.

PubMed ID: 33567701

Synbiotic increased fecal butyrate and beneficial bacteria — supports digestion.

PubMed ID: 34102559

Bovine lactoferrin reduced diarrhea morbidity in infants—clear digestive benefit, though associated with lower fecal butyrate.

PubMed ID: 34365905

GOS in lactose-intolerant adults increased bifidobacteria and butyrate-producing taxa, a favorable change for digestion in this population.

PubMed ID: 33382352

Six-week inulin increased circulating butyrate and shifted butyrate-associated taxa — supports digestive health and fermentation balance.

PubMed ID: 33671147

RS2 wheat increased breath fermentation markers and butyrate‑associated taxa — evidence of altered colonic fermentation that can influence digestion.

PubMed ID: 36055959

Mediterranean diet increased fecal butyrate and improved gut‑permeability markers — consistent with improved digestive health.

PubMed ID: 36003050

Probiotic increased fecal butyrate and reduced infant eczema severity; improvements in atopic manifestations suggest fewer immune‑mediated sensitivities linked to SCFA increases.

PubMed ID: 35079761

Probiotic increased fecal butyrate and improved stool consistency and responder rate in chronic constipation.

PubMed ID: 36130222

Almond consumption raised fecal butyrate and stool frequency in humans—supports digestive benefit from increased butyrate.

PubMed ID: 36717369

RCT in IBS‑D: probiotic raised fecal butyrate and produced large symptomatic improvement—strong indirect evidence that butyrate supports digestion.

PubMed ID: 35102419

Resistant‑starch wheat raised fecal butyrate and beneficial bacteria, consistent with improved digestive health.

PubMed ID: 35833889

Germinated brown rice raised stool SCFAs and altered microbiota (Bacteroides), supporting digestion.

PubMed ID: 35029612

In celiac patients, rises in butyrate‑producing bacteria correlated with tolerance to a modified gluten bread.

PubMed ID: 35185013

Neonatal probiotics raised fecal butyrate/propionate—supports digestive ecosystem though clinical feed outcomes unchanged.

PubMed ID: 36499011

Rhubarb RCT produced meaningful increases in stool frequency/consistency and fecal butyrate—direct digestive benefit.

PubMed ID: 35500381

Fermented brown rice increased SCFA production and butyrate‑associated taxa in metabolic syndrome—favors digestive health.

PubMed ID: 35938351

Probiotic diet increased fecal butyrate and beneficial taxa—consistent with improved digestive milieu and decreased inflammation (hsCRP).

PubMed ID: 36678227

Probiotics increased fecal SCFAs (including butyrate) and reduced chemotherapy‑related diarrhea, abdominal pain and other GI symptoms.

PubMed ID: 37367942

Higher abundance of a butyrate producer (A. hadrus) correlated with less chemo‑related diarrhea—observational support for digestive benefit.

PubMed ID: 37751049

30-day GOS gummy in constipated adults improved constipation symptoms and increased butyrate — strong direct evidence for bowel regularity benefit.

PubMed ID: 36678227

Probiotic supplementation during chemo raised SCFAs and significantly reduced diarrhea and other GI complications.

PubMed ID: 37451270

FMT enriched butyrate‑producing guilds and improved gut integrity—relevant to colon health though study focused on neuropathy outcomes.

PubMed ID: 35938351

Raised fecal butyrate and beneficial taxa in seniors supports colonocyte nourishment and colon health.

PubMed ID: 35268024

Increased fecal butyrate and butyrate-producers—directly relevant to colonocyte energy and colon health.

PubMed ID: 35500381

Fermented brown rice raised butyrate‑associated bacteria and SCFA production in metabolic syndrome—colon health implications.

PubMed ID: 36499011

Rhubarb RCT showed clear, dose‑dependent increases in stool frequency/consistency and raised fecal butyrate.

PubMed ID: 35185013

Probiotics increased fecal propionate and (with multistrain) butyrate in extremely preterm infants—direct SCFA increase relevant to colon health.

PubMed ID: 35833889

Germinated brown rice increased stool SCFAs including butyrate in T2D participants—relevant to colon health.

PubMed ID: 35102419

Resistant‑starch wheat increased fecal butyrate (major colonocyte fuel) and upregulated beneficial species—supports colon health.

PubMed ID: 36717369

IBS‑D probiotic increased butyrate and substantially improved diarrhea symptoms and composite response.

PubMed ID: 36130222

Almonds raised fecal butyrate and increased stool frequency in an RCT—direct link to bowel regularity.

PubMed ID: 35079761

Probiotic intervention increased fecal butyrate and improved spontaneous bowel movements and stool form in chronic constipation.

PubMed ID: 36055959

Dietary intervention raised fecal butyrate and improved intestinal permeability markers — changes supportive of colon health.

PubMed ID: 33382352

Inulin raised systemic butyrate and shifted butyrate-associated taxa — relevant because butyrate is a primary energy source for colonocytes and supports colon health.

PubMed ID: 34365905

GOS increased several butyrate-producing taxa (Coprococcus, Faecalibacterium) in humans — supports colon microbial ecology.

PubMed ID: 34102559

Bovine lactoferrin reduced diarrhea episodes (clinical stool-frequency/consistency improvement).

PubMed ID: 33567701

Synbiotic increased fecal butyrate — supports colonocyte health and fermentation balance.

PubMed ID: 32564657

Presence of butyrate-producing Lachnospiraceae post-surgery predicted maintenance of remission—strong colon-health signal.

PubMed ID: 32945066

FMT raised fecal butyrate substantially; butyrate is a key colonocyte fuel and higher levels correlated with symptom benefit.

PubMed ID: 33388204

Dietary changes increased butyrate‑producing taxa and reduced zonulin, supporting colonic mucosal health.

PubMed ID: 32476236

Trial of oral sodium butyrate in ulcerative colitis (a colon disease) produced microbiota shifts toward butyrogenic taxa and improved patient QoL — clinically relevant to colon health.

PubMed ID: 31797399

Probiotic raised fecal butyrate — butyrate is central to colonocyte health; trial gives indirect human support for colon health benefits.

PubMed ID: 30145102

After H. pylori therapy, participants given C. butyricum had increased organism abundance and improved defecatory symptoms (human clinical symptom improvement consistent with more regular bowel function).

PubMed ID: 30716942

Directly relevant: intervention increased fecal butyrate (key colonocyte fuel) and reduced gut-derived toxins (p-CS, IS), indicating improved colonic biochemical environment—strong supportive evidence for colon health in this context.

PubMed ID: 30400947

Raised plasma and presumably colonic butyrate and fermentation markers over short term—supports colonic fermentation and related colonocyte substrate availability.

PubMed ID: 28063242

Butyrate improved intestinal morphology and decreased endotoxin translocation in animals—supports colon/intestinal health (translational caveat).

PubMed ID: 28954842

Whole-grain rye/wheat increased fecal butyrate and produced a modest but measurable increase in stool frequency in overweight adults.

PubMed ID: 28179226

Whole-grain intake increased total SCFAs and altered taxa that are associated with colonic fermentation and health.

PubMed ID: 28410921

Resistant starch increased stool butyrate and favorable microbiome changes—outcomes commonly interpreted as supportive of colon health.

PubMed ID: 28214040

Arabinoxylan raised fecal butyrate and total SCFAs, which are important for colonocyte nutrition and colon health.

PubMed ID: 31688306

UC flare subgroup demonstrates fecal butyrate declines associated with disease activity — strong signal for colon health relevance.

PubMed ID: 34956218

Oat intervention increased butyrate‑producer taxa (Roseburia) and SCFAs—directly relevant to supporting colon health via increased butyrate production (human RCT evidence for microbial/SCFA changes).

PubMed ID: 33188417

Whole‑grain prevented liver‑fat increase and increased predicted butyrate fermentation — supports colon microbial function and systemic benefit.

PubMed ID: 17623227

Human increase in fecal butyrate and bifidobacteria suggests beneficial effects for colon ecosystem and health.

PubMed ID: 31686768

Robust increase in stool frequency in mildly constipated adults after prebiotic supplementation increasing butyrate-producer abundance.

PubMed ID: 39189588

Postbiotic intervention significantly improved defecation frequency and chronic diarrhea symptoms while increasing fecal butyrate — strong direct evidence.

PubMed ID: 8164297

Substantial human increase in butyrate after fiber intake — supports colonocyte nutrition and general colon health (indirect evidence).

PubMed ID: 7654893

Direct clinical benefit in distal UC with SCFA enemas supports colon-specific therapeutic effects.

PubMed ID: 9706795

Fermented oats increased stool volume and fecal SCFAs, consistent with improved regularity.

PubMed ID: 10022641

Fiber-induced increases in fecal butyrate associated with maintenance of ulcerative colitis remission—supports colon health via endogenous SCFA production.

PubMed ID: 12038477

Demonstrated increased fecal bulk (stool bulk) with fine wheat bran—direct support for improved bowel regularity (strong evidence for stool output change).

PubMed ID: 10795763

Oral butyrate improved UC endoscopic/histologic scores, supporting colonic health.

PubMed ID: 11053512

Acarbose increased fecal butyrate and rectal crypt proliferation (BrdU) and correlated with Ki‑67—relevant to colon mucosal health and cancer-protective hypotheses.

PubMed ID: 12641543

Topical butyrate produced remission and mucosal improvement in distal UC, directly supporting colon health in an inflammatory-colon condition.

PubMed ID: 16469156

Human lupin‑fibre trial increased stool output and defecation frequency (+0.13 events/d) and sped transit — strong direct evidence for improving regularity mediated by increased faecal butyrate.

PubMed ID: 19224658

Study shows lower faecal butyrate and reduced defecation frequency on a low‑carb diet, implying butyrate levels associate with bowel frequency.

PubMed ID: 19480733

Direct sodium butyrate supplementation in piglets altered intestinal morphology and improved digestibility—animal evidence relevant to colon health.

PubMed ID: 20018483

Increased fecal butyrate in infants suggests higher luminal butyrate availability, a recognized positive factor for colonocyte health.

PubMed ID: 20089780

Whole-grain rye shortened transit and increased weekly defecations.

PubMed ID: 20799286

Direct human evidence that MBP reduces faecal butyrate and beneficial taxa — relevant to colon ecosystem and health.

PubMed ID: 20580604

Study reported decreased defecation frequency and improved stool water content/consistency during intake—direct evidence for more regular/formed stools.

PubMed ID: 21430242

Resistant starch increased fecal butyrate in humans, supporting colonic SCFA availability associated with colonocyte health; outcomes on clinical colon health not reported.

PubMed ID: 22574737

Direct human trial using rectal sodium butyrate showed faster rectal mucosal healing and improved epithelial antimicrobial expression—strong support for colonic mucosal health.

PubMed ID: 22264499

Increased fecal butyrate and reduced endotoxaemia suggest improved colonic/intestinal environment.

PubMed ID: 22657950

AXOS elevated fecal butyrate and beneficial bacteria—supports colonocyte nutrition and colon health.

PubMed ID: 24063909

Traveler trial: treated group had fewer stools/day and far lower TD incidence, showing impact on stool frequency/consistency in humans (RCT).

PubMed ID: 23957631

Synbiotic increased butyrate production in older adults — increased colonic SCFA is linked to colon health maintenance (human RCT, indirect).

PubMed ID: 24343275

Direct randomized placebo-controlled evidence: microencapsulated sodium butyrate lowered diverticulitis episodes and improved colon-related symptoms.

PubMed ID: 23977723

Butyrylated starch produced large increases in colonic butyrate in humans and expanded butyrate‑associated taxa, directly relevant to colon health.

PubMed ID: 22738315

Microencapsulated sodium butyrate produced improvements in bowel habit/frequency in IBS patients (statistically significant).

PubMed ID: 24933989

Clinical improvements in UC/celiac patients with butyrate+inulin indicate colon mucosal benefit and disease support.

PubMed ID: 25207431

Animal evidence that butyrate derivatives reduce gut lesions and pathogen burden supports colon health (nonhuman model).

PubMed ID: 24642201

Pistachio feeding increased abundance of butyrate‑producing bacteria—beneficial for colon health though direct colon endpoints were not measured.

PubMed ID: 25726104

Sodium-butyrate promoted rumen papillae growth and tissue maturation—animal-model findings consistent with supporting large-intestine-like tissue health.

PubMed ID: 25817063

Probiotic that raised ruminal butyrate improved rumen development and weaning outcomes in calves, supporting large-intestine health via increased butyrate production (indirect).

PubMed ID: 28000678

Prebiotic-driven increases in butyrate-producing bacteria and reduced translocation/inflammation markers are consistent with colon health benefits.

PubMed ID: 27544256

Sodium butyrate reduced enteric Salmonella shedding in pigs and improved some performance measures — animal evidence supporting colon/enteric health under pathogen challenge.

PubMed ID: 26907339

Human trial measured fecal butyrate among SCFAs during dietary change — butyrate is the main colonocyte energy source and supports colon health (indirect human evidence).

PubMed ID: 39455612

Higher stool butyrate correlated with less postoperative GI dysfunction and better postoperative feeding/defecation outcomes.

PubMed ID: 39631208

Dietary patterns (cellular carbs) increased fecal butyrate; long‑term SCFA supply supports colon physiology and health.

PubMed ID: 38931207

Symbiotic meal improved bowel function in hemodialysis patients and increased stool SCFAs — direct support for regularity.

PubMed ID: 38631185

Synbiotic increased stool butyrate in humans — direct colon‑targeted SCFA increase that benefits colonocytes.

PubMed ID: 38315140

Colon‑targeted rifamycin increased stool butyrate and lowered venous ammonia with small functional gains—direct colon‑targeted intervention improving colonic metabolic markers.

PubMed ID: 39438902

FMT engrafted butyrate‑producers and reduced systemic inflammatory proteins—supports colon ecosystem health via butyrate increase.

PubMed ID: 39599737

Heat‑treated B. longum increased faecal butyrate and butyrate‑producers—supports colon microbial health and SCFA availability.

PubMed ID: 39689011

taVNS in constipation‑predominant IBS increased fecal SCFAs and improved symptoms—direct evidence for improved bowel function.

PubMed ID: 39003477

Direct RCT of oral sodium‑butyrate in UC with strong reductions in fecal calprotectin and mucosal gene changes—supports colon health.

PubMed ID: 37441828

Probiotic increased fecal butyrate (stool SCFA) in obese women—supports colonic SCFA production and colonocyte substrate availability.

PubMed ID: 36856122

Synbiotic raised colonic SCFAs including butyrate in overweight children, supporting colon metabolic health.

PubMed ID: 37111201

Synbiotic improved gut microbial composition and reduced adverse events; plausible benefit for bowel function though not primary endpoint.

PubMed ID: 37898434

Dietary wholegrain increased fecal butyrate, modulated microbiota and improved lipid markers — supportive of colon health.

PubMed ID: 37367942

Higher A. hadrus abundance associated with less chemotherapy‑related diarrhea—observational evidence for improved bowel consistency/frequency.

PubMed ID: 28077379

Downregulation of SFRP1 and reductions in β‑catenin/c‑MYC in rectal mucosa after fermentable fiber (butyrate‑linked) suggests a protective effect on pathways relevant to colorectal carcinogenesis.

PubMed ID: 41261535

Trial showed increased spontaneous bowel movements alongside rises in butyrate‑producing taxa and fecal SCFAs—direct clinical evidence for regularity benefit linked to butyrate.

PubMed ID: 40947861

Direct RCT of butyrylated starch (colon‑targeted butyrate delivery) in FAP patients raised fecal butyrate and altered pH; trial focused on colon pathology (polyps), so it is directly relevant to colon health.

PubMed ID: 40751371

Sustained increases in fecal butyrate after FMT correlated with lasting symptom improvement in IBS, supporting colonic health.

PubMed ID: 41354580

Butyrate improved IBD clinical indices and reduced fecal calprotectin—direct benefit to colonic health.

PubMed ID: 40081693

Improved permeability and reduced inflammation markers after butyrate supplementation suggest supportive effects on colon health.

PubMed ID: 40565024

Calcium butyrate reduced fecal calprotectin in MASLD cohort — an indicator relevant to colonic inflammation/health.

PubMed ID: 41422374

Butyrate supplementation produced higher fecal butyrate and clinically meaningful improvements in mild‑to‑moderate ulcerative colitis.

PubMed ID: 40274191

Inulin increased butyrate production (tracer modeling) and fecal/plasma SCFAs — physiologic support for colonic health.

PubMed ID: 41233756

Four weeks of inulin increased weekly stool frequency and improved constipation measures in a randomized crossover.

PubMed ID: 40366770

Probiotic+inulin increased fecal butyrate and microbiome genes tied to SCFA production, supporting colon health.

PubMed ID: 40167641

Oral sodium butyrate improved permeability markers implicated in colonic mucosal health.

PubMed ID: 40635319

Oral calcium butyrate produced strong symptomatic improvement in pediatric IBS with microbiome/metabolome changes linked to colonic health.

PubMed ID: 40575487

SCFA‑producing probiotic raised fecal butyrate and improved intestinal barrier and symptoms—benefits to colonic mucosa.

PubMed ID: 40286792

Postbiotic RCT produced clinically meaningful increases in weekly bowel movements and reduced straining while raising fecal butyrate.

PubMed ID: 39153842

Probiotic increased fecal butyrate in preterm infants, suggesting more substrate for enterocyte energy (indirect).

PubMed ID: 40182598

Probiotic drink raised stool butyrate (directly increasing substrate available to colonocytes) — supports colonic cell energy supply (indirect measurement).

PubMed ID: 41422374

Supplemental sodium butyrate increased fecal butyrate and improved mucosal healing in UC, consistent with improved colonocyte energy supply.

PubMed ID: 40274191

Tracer study showed increased microbial butyrate production and rises in fecal/plasma SCFAs—direct evidence of increased substrate for colonocyte energy.

PubMed ID: 40366770

Probiotic+inulin raised fecal butyrate levels, providing the primary energy source for colonocytes.

PubMed ID: 40167641

Oral sodium butyrate improved markers of gut integrity and function, consistent with enhanced mucosal energy/metabolism.

PubMed ID: 40635319

Oral calcium butyrate produced strong symptomatic improvement in IBS children—consistent with butyrate acting as colonocyte fuel and improving mucosal function.

PubMed ID: 40575487

SCFA‑producing probiotic raised fecal butyrate which supports colonocyte energy metabolism and barrier maintenance.

PubMed ID: 40286792

Postbiotic increased fecal butyrate (primary fuel for colonocytes), supporting the idea of increased energy availability to intestinal cells.

PubMed ID: 38957464

The probiotic trial produced a large measured increase in fecal butyrate (µg/mL), directly increasing the luminal substrate used by colonocytes as energy—strong mechanistic/clinical support.

PubMed ID: 38199487

Colon‑targeted butyrate increased serum butyrate after delivery to the colon — direct evidence that colonic butyrate is absorbed and available to tissues (including colonocytes).

PubMed ID: 38315140

Colon‑targeted rifamycin increased stool butyrate concentrations—directly relevant to supplying colonocytes with their preferred energy substrate.

PubMed ID: 39438902

FMT engrafted butyrate‑producing taxa and decreased inflammatory proteins—microbiome shift implies increased local butyrate availability to colonocytes.

PubMed ID: 39599737

Heat‑treated B. longum increased fecal butyrate and butyrate‑producers—direct increase in the SCFA that is primary fuel for colonocytes, supporting intestinal cell energetics.

PubMed ID: 39003477

Oral sodium‑butyrate in UC improved mucosal gene expression and inflammation—supports the role of butyrate as colonocyte energy source and mucosal recovery.

PubMed ID: 37441828

Increased fecal butyrate after probiotic implies more luminal substrate for colonocytes (stool measure, indirect).

PubMed ID: 37111201

Synbiotic restored SCFA-producing microbes, implying increased butyrate availability for epithelial energy.

PubMed ID: 37898434

Wholegrain diet raised fecal/plasma butyrate supporting colonocyte energy supply (indirect dietary evidence).

PubMed ID: 37751049

Marked increases in butyrate (a primary colonocyte fuel) support this mechanism; study demonstrated raised butyrate levels.

PubMed ID: 36594522

Prebiotic increased butyrate‑producers—suggests increased colonic butyrate as an energy source, though direct SCFA measurements were secondary.

PubMed ID: 37367942

Correlation between A. hadrus abundance and fecal butyrate supports increased local energy substrate availability (observational).

PubMed ID: 36678227

Probiotics increased fecal SCFAs including butyrate—direct substrate that supplies energy to colonocytes.

PubMed ID: 37451270

FMT enriched butyrate‑producing microbes, increasing potential local butyrate supply for intestinal cells.

PubMed ID: 35938351

Raised fecal butyrate in an RCT context strongly supports increased substrate availability for colonocytes.

PubMed ID: 35943883

Short-term fecal butyrate increase indicates increased available SCFA energy for gut epithelium (moderate confidence).

PubMed ID: 35268024

Direct increase in fecal butyrate (major colonocyte fuel) provides strong mechanistic support for providing energy to intestinal cells.

PubMed ID: 35500381

Fermented brown rice increased butyrate‑producing taxa and SCFA production—relevant to colonocyte energy.

PubMed ID: 36499011

Rhubarb raised fecal butyrate meaningfully—supports intestinal cell energy.

PubMed ID: 35185013

Probiotics raised fecal butyrate in preterm infants—supports colonocyte energy supply.

PubMed ID: 36517799

Prebiotic markedly increased circulating butyrate (direct colonocyte energy substrate)—strong mechanistic support.

PubMed ID: 35102419

Resistant‑starch intervention increased fecal butyrate (primary colonocyte fuel)—direct mechanistic support for providing energy to intestinal cells.

PubMed ID: 36003050

Probiotic intervention increased fecal butyrate in infants, implying increased substrate for colonocytes and mucosal health.

PubMed ID: 36055959

Mediterranean diet increased colonic SCFAs (butyrate) and improved permeability markers; butyrate is the principal fuel for colonocytes, supporting cellular energy.

PubMed ID: 33382352

Inulin raised circulating butyrate — butyrate is the primary energy source for colonocytes, so this provides direct biochemical support.

PubMed ID: 34365905

GOS increased several butyrate-producing taxa (Coprococcus, Faecalibacterium) that supply butyrate to intestinal cells.

PubMed ID: 33567701

Synbiotic increased fecal butyrate — direct source of colonocyte energy.

PubMed ID: 31927581

Demonstrated a small but measurable serum butyrate increase on a high‑protein high‑fiber diet—plausibly increases substrate availability for colonocyte energy.

PubMed ID: 32564657

Higher abundance of butyrate-producing taxa (which supply colonocyte energy) associated with better surgical outcomes—indirect support.

PubMed ID: 32945066

FMT increased fecal butyrate (primary fuel for colonocytes) substantially — direct support for epithelial energy supply.

PubMed ID: 30716942

Strong mechanistic relevance: study documented increased fecal butyrate, the primary energy substrate for colonocytes—direct biochemical support though no direct cellular uptake measures were done.

PubMed ID: 28063242

Butyrate increased absorptive epithelial cell area and villus measures in animals—consistent with provision of energy to colonocytes and improved epithelial health.

PubMed ID: 28410921

Resistant starch increased stool butyrate (primary colonocyte fuel), supporting the concept that colonic butyrate production supplies energy to intestinal cells.

PubMed ID: 28214040

Arabinoxylan increased fecal butyrate and total SCFAs, which are substrates for colonocyte energy metabolism.

PubMed ID: 27065265

Cecal butyrate increased in certain diets and correlated with improved digestibility in pigs — strong animal evidence that butyrate supplies colonocyte energy and improves gut function.

PubMed ID: 26907339

Human dietary trial measured fecal butyrate (one of the SCFAs) during energy restriction, supporting the idea of butyrate as a colonocyte energy source (indirect human data).

PubMed ID: 27548249

Increase in Roseburia (butyrate producer) in infants suggests increased local butyrate production and therefore epithelial energy supply (human).

PubMed ID: 28000678

Prebiotic-induced increases in butyrate-producing taxa and butyrate levels imply more substrate for colonocyte energy metabolism.

PubMed ID: 26015588

Encapsulated butyric acid supplementation in broilers indicates functional benefits of butyrate in the gut; butyrate is a known primary energy substrate for colonocytes—animal trial supports this role though direct enterocyte energy measures were not reported.

PubMed ID: 25817063

M. elsdenii increased ruminal butyrate and markers (papillae, BHBA) indicative of enhanced energy substrate availability to rumen/intestinal tissues (indirect animal evidence).

PubMed ID: 25726104

Sodium-butyrate supplementation led to rumen papillae growth and increased SCFA, consistent with butyrate serving as fuel for mucosal cells (animal evidence).

PubMed ID: 25207431

Butyric acid glycerides improved gut lesion outcomes in chickens; consistent with improved epithelial cell energy/support (animal data).

PubMed ID: 24933989

Oral butyrate supplementation in patients with gut disease produced mucosal/microbiota benefits consistent with providing energy to intestinal cells (combined therapy caveat).

PubMed ID: 23977723

Human butyrylated starch markedly increased luminal butyrate, which is the primary fuel for colonocytes—direct mechanistic support.

PubMed ID: 24385355

Probiotic increased fecal butyrate (endogenous), which is a primary energy source for colonocytes (indirect evidence).

PubMed ID: 23957631

Synbiotic RCT increased colonic butyrate production in humans; butyrate is primary energy source for colonocytes, so this directly supports the benefit.

PubMed ID: 22657950

AXOS-enriched bread significantly increased fecal butyrate levels—supports provision of energy to intestinal cells.

PubMed ID: 22264499

XOS increased fecal butyrate—consistent with increased colonocyte energy supply (not directly measured).

PubMed ID: 22574737

Butyrate is a known colonocyte energy substrate; the enemas produced epithelial healing, consistent with provision of energy to intestinal cells in humans (inferred though not directly measured).

PubMed ID: 20580604

Study directly documents increased stool butyric acid after probiotic intake; butyrate is the primary fuel for colonocytes—strong mechanistic relevance.

PubMed ID: 20799286

Human study showing MBP lowered faecal butyrate — direct implication that colonocytes temporarily lose a primary energy substrate.

PubMed ID: 39189588

Postbiotic raised fecal butyrate (primary fuel for colonocytes) and improved bowel symptoms — consistent with increased colonic epithelial energy supply.

PubMed ID: 31686768

Increase in a major butyrate-producing bacterium supports the premise that butyrate availability (colonocyte fuel) is increased—study provides the most direct human microbiome evidence in the dataset.

PubMed ID: 17623227

Human trial demonstrated increased fecal butyrate — butyrate is the primary energy source for colonocytes; direct cellular energy measures absent.

PubMed ID: 15080850

Direct measurement of fecal butyrate (the main colonocyte fuel) is evidence that treatments affect the substrate supply to intestinal epithelial cells.

PubMed ID: 31688306

Direct measurement: fecal butyrate decreased during UC flares — butyrate is primary colonocyte fuel, so this supports energy role.

PubMed ID: 22357741

Strong preclinical signal: luminal butyrate associated with upregulated MCT1 expression in pig colon, indicating increased uptake and utilization of SCFAs by epithelial cells (direct mechanism).

PubMed ID: 20089780

Whole-grain rye raised fecal butyrate substantially — supports colonocyte fuel supply.

PubMed ID: 19480733

Butyrate is a known colonocyte energy substrate and piglet outcomes (mucosal/intestinal changes, growth) support functional effects on intestinal cells.

PubMed ID: 16469156

Lupin fibre increased faecal butyrate in humans — since butyrate is primary fuel for colonocytes, this human evidence indirectly supports increased energy availability to intestinal cells.

PubMed ID: 12641543

Clinical mucosal healing with topical butyrate implies improved epithelial cell health/energy utilization, although the study did not measure cellular metabolism directly.

PubMed ID: 11053512

Acarbose raised fecal butyrate and increased BrdU uptake in rectal crypts—consistent with butyrate serving as energy/substrate for colonocytes.

PubMed ID: 10795763

Oral sodium butyrate improved mucosal histology in UC, consistent with supporting colonocyte health/energy.

PubMed ID: 12038477

Directly measured increased fecal butyrate output—butyrate is the primary energy source for colonocytes, so this provides strong mechanistic support (though no direct cellular energy measures were made).

PubMed ID: 10022641

Plantago ovata raised fecal butyrate levels, implying increased substrate availability for colonocyte energy metabolism.

PubMed ID: 7654893

Direct delivery of SCFA (including butyrate) via enemas supplies colonocytes and improved mucosal outcomes in UC.

PubMed ID: 8164297

Human study directly measured a ~90% increase in butyrate after fiber intake — butyrate is the main energy source for colonocytes (strong indirect human support).

PubMed ID: 33167908

Directly measures increased stool butyrate and butyrate‑producers — butyrate is a primary energy source for colonocytes; this provides moderate indirect support for increased substrate availability.

PubMed ID: 32330237

Higher fecal butyrate in breastfed infants suggests greater SCFA supply to colonocytes (observational human data).

PubMed ID: 41261535

Fecal SCFAs including butyrate increased after intervention—directly relevant to colonocyte energy supply.

PubMed ID: 41197269

Probiotic increased fecal butyrate production—supports increased substrate availability for intestinal epithelial cells.

PubMed ID: 40947861

Butyrylated resistant starch delivered butyrate to the colon (raised fecal butyrate), providing substrate for colonocyte energy metabolism — direct mechanistic evidence of energy provision.

PubMed ID: 40751371

Durable increases in fecal butyrate after FMT imply greater luminal butyrate availability to colonocytes (supports cellular energy).

PubMed ID: 40577952

Oral butyrate reduced circulating markers tied to gut permeability and inflammation (zonulin, LBP).

PubMed ID: 41094562

Plasma butyrate increase correlated with reductions in IL‑6 and other inflammatory proteins in a randomized synbiotic trial.

PubMed ID: 40167641

Sodium butyrate lowered LBP and zonulin, consistent with reduced systemic inflammatory stimulus from the gut.

PubMed ID: 40635319

Pediatric calcium butyrate gave large symptom benefits and microbiome/metabolome changes consistent with lower gut inflammation.

PubMed ID: 40575487

Probiotic RCT improved intestinal permeability and inflammatory markers while increasing fecal SCFAs.

PubMed ID: 39575188

Fenofibrate add‑on to mesalamine in UC lowered several inflammatory biomarkers — clinical anti‑inflammatory evidence (drug trial).

PubMed ID: 38631185

Synbiotic raised fecal SCFAs and IL‑10 (anti‑inflammatory) in RCT — broad anti‑inflammatory implication.

PubMed ID: 38315140

Colon‑targeted rifamycin reduced ammonia and raised butyrate with small improvements in functional markers—compatible with reduced inflammatory/metabolic stress.

PubMed ID: 39438902

FMT from butyrate‑rich donors markedly reduced many circulating inflammatory proteins over 24 weeks—strong evidence for lowering systemic inflammation via a butyrate‑rich microbiome.

PubMed ID: 38865630

Rifaximin+probiotic+prebiotic regimen reduced IL‑6 and increased IL‑10 while raising stool butyrate—supports reduced gut/systemic inflammation.

PubMed ID: 39408351

Direct sustained‑release butyrate lowered activated Th cells and IL‑9+ Th cells and improved Th17/Treg ratio—evidence for anti‑inflammatory effects relevant to gut immunity.

PubMed ID: 39003477

Sodium‑butyrate RCT in mild–moderate UC produced large between‑group reduction in fecal calprotectin (direct anti‑inflammatory effect in gut).

PubMed ID: 38135194

Butyrate capsule reduced zonulin (gut leak) and markers linked to NMJ loss; suggests reduction in gut‑related inflammatory signals in COPD patients.

PubMed ID: 37111201

Synbiotic restored beneficial microbes and reduced short-term adverse outcomes; SCFA-related anti-inflammatory effects are plausible.

PubMed ID: 37898434

Wholegrain increased SCFAs which have anti-inflammatory properties; evidence is dietary and indirect.

PubMed ID: 36594522

Metabolic improvements with prebiotic intervention may reflect reduced metabolic/inflammatory stress though direct cytokine changes were not primary endpoints.

PubMed ID: 37367942

Higher A. hadrus (butyrate producer) correlated with fewer inflammatory complications (febrile neutropenia/diarrhea) in chemo patients.

PubMed ID: 36678227

Probiotic group showed higher fecal SCFAs and fewer inflammatory GI complications during chemotherapy.

PubMed ID: 37451270

FMT reduced systemic proinflammatory cytokines and improved gut barrier alongside enrichment of butyrate producers.

PubMed ID: 35938351

Significant hsCRP reduction alongside increased fecal butyrate after probiotic diet indicates lowered systemic inflammation.

PubMed ID: 35029612

Celiac study found increases in butyrate‑producers were associated with lower inflammatory signatures in some clusters.

PubMed ID: 36359816

Synbiotic RCT showed reductions in systemic inflammatory markers and increased predicted butyrate metabolism—strong indirect evidence linking butyrate pathways to lower inflammation.

PubMed ID: 36717369

IBS‑D probiotic increased fecal butyrate and improved symptoms; likely reduced local gut inflammation (indirect).

PubMed ID: 36003050

Probiotic increased fecal butyrate and improved eczema (an inflammatory skin condition), suggesting decreased systemic/immune inflammation associated with higher butyrate.

PubMed ID: 36055959

Mediterranean diet increased fecal SCFAs and lowered biomarkers associated with endotoxin exposure (LBP) and zonulin, consistent with reduced gut‑driven inflammation.

PubMed ID: 36469320

Oral butyrate significantly reduced IL‑6 and improved inflammatory profile in overweight children, indicating lower systemic inflammation.

PubMed ID: 34534897

Reduced zonulin and correlations with butyrate-producers suggest lower mucosal inflammation risk after the polyphenol diet.

PubMed ID: 32564657

Butyrate-producer–enriched communities were associated with reduced Crohn’s disease recurrence—consistent with lower intestinal inflammation.

PubMed ID: 32475312

Randomized crossover showed modest sodium reduction increased circulating SCFAs (including butyrate) and improved BP/arterial stiffness—consistent with lower systemic inflammation.

PubMed ID: 32315958

Oral sodium butyrate markedly downregulated inflammasome/pyroptosis pathway genes (NLRP3, IL‑1β/IL‑18 etc.).

PubMed ID: 31797399

Probiotic increased fecal butyrate and reduced colic symptoms; butyrate has anti-inflammatory actions — indirect human evidence for lower gut inflammation.

PubMed ID: 30550821

In pediatric Crohn's disease, the food-based diet produced large decreases in fecal calprotectin (mean drop ~918 mg/kg, P = .002) and clinical response/remission—direct evidence of reduced intestinal inflammation linked to microbiome/metabolite changes.

PubMed ID: 28063242

Butyrate reduced serum endotoxin and histologic villus injury in chickens, implying lower gut inflammation (animal evidence).

PubMed ID: 28410921

Resistant starch reduced Proteobacteria dysbiosis (often linked to inflammation) and increased butyrate; these microbiome shifts plausibly reduce colonic inflammation though inflammation markers were not primary outcomes.

PubMed ID: 26852904

Human FFA2 antagonist study shows SCFA signalling (receptor for SCFAs including butyrate) dose‑dependently influences neutrophil activation — mechanistic human support that SCFAs modulate inflammatory responses.

PubMed ID: 28000678

Reported decreases in systemic/inflammatory markers (hsCRP, sCD14) along with increased butyrate production, consistent with reduced gut-related inflammation.

PubMed ID: 25207431

Butyric acid glycerides reduced lesion scores and parasite burden in broilers—evidence of reduced local gut inflammation (animal model).

PubMed ID: 24933989

In patients with inflammatory gut conditions, butyrate+inulin was associated with clinical improvement (strongest clinical signal in dataset).

PubMed ID: 24343275

Sodium butyrate reduced incidence of clinical and imaging-diagnosed diverticulitis—direct evidence of reduced gut inflammatory events.

PubMed ID: 23957631

Synbiotic RCT lowered blood TNF-α while increasing butyrate production — strong human evidence of reduced inflammation linked to SCFA increase.

PubMed ID: 24063909

Traveler RCT showed milder GI symptoms with sodium butyrate/SCFA, consistent with reduced acute gut inflammation in humans.

PubMed ID: 22264499

Reduced circulating LPS and attenuated LPS‑induced cytokine responses after INU+XOS indicate a reduction in systemic/gut‑related inflammation.

PubMed ID: 22574737

Sodium-butyrate enemas in adults with shigellosis markedly reduced mucosal inflammation, stool inflammatory cells and IL-8—strong human evidence of local anti-inflammatory effects.

PubMed ID: 15063428

Atorvastatin normalized circulating sFasL and had effects on endothelial inflammatory signalling — relevant to systemic inflammation modulation.

PubMed ID: 12641543

Significant clinical and endoscopic remission/improvement in refractory distal UC with topical butyrate indicates strong local anti-inflammatory effect.

PubMed ID: 11053512

Acarbose raised fecal butyrate and altered mucosal proliferation markers; plausible anti-inflammatory mucosal effects though not a direct inflammation trial.

PubMed ID: 10795763

Sodium butyrate added to mesalazine produced greater clinical and histologic improvement in UC, an inflammatory gut disease.

PubMed ID: 10022641

Plantago ovata increased fecal butyrate and maintained UC remission comparably to mesalamine, suggesting an anti-inflammatory contribution from increased SCFA.

PubMed ID: 8943981

Butyrate enemas showed trends toward improvement in disease activity and endoscopic segments in active distal UC, indicating potential anti‑inflammatory effects (underpowered).

PubMed ID: 7654893

Randomized trial: SCFA enemas improved clinical, endoscopic and histologic scores in distal ulcerative colitis vs placebo — strong anti‑inflammatory effect locally.

PubMed ID: 8164297

Human fiber trial showed a large rise in butyrate — a metabolite with known systemic/intestinal anti‑inflammatory actions (but inflammation not measured here).

PubMed ID: 39189588

Increased fecal butyrate and improved chronic diarrhea outcomes are consistent with reduced mucosal inflammation.

PubMed ID: 31686768

Lower serum LPS (endotoxin) implies reduced systemic exposure to pro-inflammatory microbial products—supportive of reduced gut-related inflammation.

PubMed ID: 31688306

In UC patients, fecal butyrate fell during flares — directly implicates butyrate levels in intestinal inflammation/exacerbation.

PubMed ID: 30916575

Peri‑transplant milk reduced plasma IL‑8/IL‑10 (markers of intestinal inflammation) despite no stool butyrate change — shows gut inputs can modulate inflammation.

PubMed ID: 34956218

Oat RCT increased SCFA producers and improved lipids—microbial SCFA increases (including butyrate producers) have anti‑inflammatory associations (human RCT microbial/SCFA evidence).

PubMed ID: 41261535

Increased fecal SCFAs and butyrate producers after intervention may reduce local inflammation in the gut (moderate indirect evidence).

PubMed ID: 40824724

Higher circulating SCFAs (including butyrate) were robustly associated with lower genital inflammatory cytokines in a well‑powered observational study.

PubMed ID: 41197269

Probiotic increased butyrate and decreased Th2 cytokines and IgE with symptomatic improvement in allergic rhinitis—supports anti‑inflammatory effects linked to butyrate generation.

PubMed ID: 40947861

Butyrylated starch increased colonic butyrate — mechanistically associated with anti‑inflammatory effects in the colon, though clinical inflammation endpoints (polyp counts) were unchanged.

PubMed ID: 40421856

Prebiotic/physio interventions that raised fecal butyrate also decreased endotoxin and some inflammatory markers.

PubMed ID: 40751371

Higher fecal butyrate after FMT correlated inversely with IBS symptom scores and fatigue, consistent with lower gut inflammation.

PubMed ID: 41327655

TCM decoction increased stool butyrate and reduced serum D‑lactate; clinical improvement accompanied SCFA increases (indirect anti‑inflammatory signal).

PubMed ID: 41354580

Randomized trial of oral butyrate in IBD reduced fecal calprotectin and clinical disease activity—strong direct evidence for reduced gut inflammation.

PubMed ID: 40081693

Butyrate lowered CRP and LBP in OA patients, indicating decreased systemic inflammation.

PubMed ID: 40565024

Calcium butyrate reduced fecal calprotectin over time in MASLD subgroup analyses — indicates reduced intestinal inflammation marker.

PubMed ID: 41422374

Microencapsulated sodium butyrate increased fecal butyrate and significantly improved clinical and endoscopic remission in UC (reduced gut inflammation).

PubMed ID: 39438902

FMT from butyrate‑rich donors produced sustained decreases in many circulating inflammatory proteins and increased butyrate‑producers—strong evidence for immune modulation via butyrate‑rich microbiota.

PubMed ID: 31688306

Ulcerative colitis subgroup shows fecal butyrate falls with flare/mesalamine — implicates butyrate in mucosal immune status.

PubMed ID: 40824724

Higher circulating SCFAs (including butyrate) were inversely associated with genital inflammatory cytokines, supporting an anti‑inflammatory/immune‑modulatory role.

PubMed ID: 41197269

Probiotic raised fecal butyrate and was associated with reduced Th2 inflammation and improved allergic symptoms—strong, direct immune-related effect linked to increased butyrate.

PubMed ID: 41354580

Oral butyrate RCT reduced fecal calprotectin and improved disease activity in IBD, indicating local immunomodulation.

PubMed ID: 40081693

Butyrate supplementation lowered systemic CRP and LBP, suggesting reduced immune activation/inflammation.

PubMed ID: 41422374

Microencapsulated sodium butyrate increased fecal butyrate and raised clinical/endoscopic remission in UC, implying immune modulation.

PubMed ID: 41094562

Synbiotic raised plasma butyrate and correlated with reduced IL‑6 and other inflammatory proteins, indicating systemic immune modulation.

PubMed ID: 40167641

Sodium butyrate lowered LBP (endotoxin‑related marker) and zonulin, suggesting reduced immune activation from gut leak.

PubMed ID: 40575487

SCFA‑producing probiotic increased fecal butyrate and reduced intestinal permeability/inflammatory markers in IBS patients.

PubMed ID: 38957464

Randomized placebo‑controlled probiotic raised fecal butyrate and increased salivary sIgA while reducing URTI symptom days—supports an immune benefit linked to increased butyrate.

PubMed ID: 38631185

RCT showed increased fecal SCFAs (incl. butyrate) and a rise in anti‑inflammatory IL‑10 — direct immune‑relevant signal.

PubMed ID: 38865630

Rifaximin+probiotic+prebiotic raised stool butyrate and lowered IL‑6/increased IL‑10—supports immune benefit tied to higher butyrate (multi‑agent intervention).

PubMed ID: 39408351

Sustained‑release oral butyrate reduced ex vivo T‑helper activation and IL‑9+ Th cells and improved Th17/Treg balance in OA patients—direct immunomodulatory evidence.

PubMed ID: 39003477

Oral sodium‑butyrate reduced fecal calprotectin (marker of intestinal inflammation) in UC—strong immune‑modulatory signal in gut.

PubMed ID: 37940573

Black‑tea intervention increased abundance of butyrate‑producing bacteria and was linked to improved mucosal immunity markers.

PubMed ID: 37111201

Synbiotic reduced short-term adverse health events and restored beneficial microbes — supports microbiome-mediated immune benefit.

PubMed ID: 37367942

Higher Anaerostipes hadrus (butyrate producer) associated with markedly lower febrile neutropenia risk during chemo (observational link to immune resilience).

PubMed ID: 36678227

Probiotics raised fecal SCFAs (including butyrate) and reduced chemo GI complications—indirectly supportive of mucosal immune health.

PubMed ID: 37451270

Healthy‑donor FMT increased butyrate‑producing guilds and lowered proinflammatory cytokines—supports immune modulation.

PubMed ID: 35938351

Probiotic diet raised fecal butyrate and lowered hsCRP—evidence of reduced systemic inflammation/immune modulation.

PubMed ID: 35276942

Deep‑sea‑derived water increased fecal sIgA alongside higher butyrate—mucosal immune enhancement.

PubMed ID: 35916813

PHGG increased fecal butyrate and correlated with fewer/less severe cold‑like symptoms (clinical immune outcome).

PubMed ID: 36359816

Synbiotic raised predicted butyrate metabolism and lowered systemic inflammatory markers (hs‑CRP, IL‑6), consistent with immune‑modulating effects.

PubMed ID: 36003050

LGG probiotic RCT increased fecal butyrate and produced clinically meaningful improvements in atopic dermatitis (immune‑mediated), linking butyrate changes to immune benefit.

PubMed ID: 36055959

Mediterranean diet increased butyrate/propionate and lowered markers of gut barrier dysfunction (LBP/zonulin), which reduces immune activation from bacterial translocation.

PubMed ID: 36469320

Oral butyrate reduced IL‑6 and improved metabolic inflammation in obese children, showing anti‑inflammatory/immune‑modulating effects.

PubMed ID: 33530034

Human cohort: reduced abundance of a butyrate-producer and lower serum butyrate preceded late-onset preeclampsia — suggests butyrate deficiency associates with immune/inflammatory dysregulation.

PubMed ID: 34102559

Bovine lactoferrin supplementation reduced respiratory infections (clinical immune benefit) though fecal butyrate decreased.

PubMed ID: 32564657

Association of butyrate-producer–enriched community with lower Crohn’s recurrence implies immunomodulatory benefits.

PubMed ID: 32315958

Sodium butyrate downregulated TLR2/4, NF-κB1, NLRP3, IL‑1β/IL‑18 and increased regulatory miRNAs — clear immunomodulatory signals.

PubMed ID: 30897686

Phage treatment reduced plasma IL-4 (immune marker) and altered gut E. coli abundance → evidence of microbiome-driven immune modulation (no stool butyrate increase).

PubMed ID: 28866384

Observational: infants who later developed eczema had lower fecal butyrate, implying a link between butyrate levels and immune-mediated skin/allergy outcomes.

PubMed ID: 28179226

Whole-grain intervention increased stool SCFAs and produced modest immune changes (effector memory T cells, LPS-stimulated TNF-α), linking SCFA increase to immune modulation.

PubMed ID: 27097436

Broiler study: dietary/feeding changes that altered fecal SCFAs (incl. butyrate) were associated with improved immune indices — supports immune-modulatory role of butyrate (animal).

PubMed ID: 26852904

First‑in‑human FFA2 antagonist trial: validates that SCFAs (receptors for butyrate) modulate neutrophil activation — mechanistic human evidence linking SCFAs to innate immunity.

PubMed ID: 27544256

Direct sodium butyrate feed reduced Salmonella faecal shedding probability in pigs — evidence for enhanced resistance to enteric pathogen challenge (animal RCT-like field trial).

PubMed ID: 28000678

Prebiotic trial increased butyrate-producing taxa and butyrate and reduced inflammatory/translocation markers (sCD14, hsCRP), indicating immune/inflammation benefits linked to butyrate.

PubMed ID: 26394045

Oral phenylbutyrate (a butyrate pro‑drug) increased antimicrobial peptide LL‑37 and, with vitamin D, improved sputum conversion in TB — strong immune effect in humans.

PubMed ID: 25207431

Butyric acid glycerides lowered parasite burden and lesions in infected broilers—evidence of enhanced local anti-parasite/immune outcomes (animal model).

PubMed ID: 23957631

Synbiotic RCT in older adults increased butyrate and bifidobacteria while lowering blood TNF-α — shows immune-modulating effects linked to increased colonic butyrate (human RCT).

PubMed ID: 22264499

INU+XOS increased fecal butyrate and reduced circulating LPS and LPS‑induced cytokine responses—direct evidence of dampened immune activation.

PubMed ID: 22574737

Butyrate enemas increased antimicrobial peptide (LL-37) expression and reduced IL-8 in stool, indicating local mucosal immune modulation in humans.

PubMed ID: 12641543

Topical sodium butyrate + 5-ASA produced greater remission and symptom improvement in refractory distal UC — consistent with an anti-inflammatory/immunomodulatory effect in the gut.

PubMed ID: 10795763

Sodium butyrate added to mesalazine reduced UC disease activity (an immune-mediated condition), indicating immunomodulatory benefit in the gut.

PubMed ID: 7654893

SCFA enema (including butyrate) improved clinical signs in ulcerative colitis — suggests modulation of local immune/inflammatory responses.

PubMed ID: 31686768

Prebiotic increased a butyrate-producing microbe and lowered serum LPS (endotoxemia), which is strongly suggestive of immune modulation via reduced endotoxin-driven immune activation.

PubMed ID: 37898434

Wholegrain intervention increased SCFAs and modestly lowered LDL/triglycerides — indicates metabolic benefits linked to SCFA production.

PubMed ID: 36594522

Prebiotic formula raised butyrate‑producers and significantly lowered HbA1c in people with type 2 diabetes (metabolic benefit).

PubMed ID: 35458231

Rye-associated plasma butyrate increases correlated with greater weight/fat loss—consistent with metabolic benefits.

PubMed ID: 35500381

Fermented brown rice increased butyrate‑associated taxa and SCFAs in metabolic‑syndrome patients—metabolic relevance.

PubMed ID: 35833889

Germinated brown rice increased SCFAs and improved fasting glucose in many T2D participants.

PubMed ID: 35730613

Longitudinal increases in serum/fecal butyrate associated with modest SBP reductions and favorable metabolic signals—strong observational link.

PubMed ID: 36469320

Oral butyrate produced meaningful improvements in BMI and HOMA‑IR in pediatric overweight/obesity — direct evidence for metabolic benefits.

PubMed ID: 34523948

Human low‑carb intervention: weight loss and increased butyrate-producing taxa correlate with metabolic improvements — moderate indirect evidence linking butyrate-producers to host metabolic outcomes.

PubMed ID: 33671147

RS2 wheat lowered postprandial glucose and insulin and shifted microbiota toward butyrate‑associated taxa, indicating metabolic improvements related to butyrate biology.

PubMed ID: 31927581

Well‑powered crossover feeding trial linking macronutrient composition to circulating SCFAs (including a modest butyrate rise) and cardiometabolic markers—indirect metabolic relevance.

PubMed ID: 32660025

Probiotic increased plasma butyrate and (in metformin subgroup) improved fasting glucose, HbA1c and HOMA‑IR.

PubMed ID: 30400947

Short-term resistant-starch/rye meals increased plasma butyrate and produced a measurable improvement in insulin sensitivity (~11%).

PubMed ID: 28924143

Reduction in fecal butyrate after high‑dose prebiotics coincided with worsened glucose tolerance, supporting a role for butyrate in healthy metabolic function (inverse evidence).

PubMed ID: 28962046

Butyrate (with/without inulin) increased GLP‑1 and produced modest improvements in fasting glucose and waist measures in people with type 2 diabetes—direct metabolic effects in humans.

PubMed ID: 17386092

Human RCT: 6 g/day oat β‑glucan modestly lowered LDL and total cholesterol; while effect is from fiber, the study demonstrated metabolic benefit alongside modelled butyrate generation (indirect link).

PubMed ID: 35411007

Oils high in ALA/omega‑3 raised butyrate‑associated taxa and associated with improved blood lipid profiles — evidence of metabolic benefit linked to butyrate producers.

PubMed ID: 33188417

Whole‑grain wheat increased predicted butyrate pathways and prevented intrahepatic triglyceride increase — relevant to metabolic health.

PubMed ID: 35179758

Energy‑restricted diet in PCOS reduced body weight and improved serum lipids while altering fecal SCFAs—direct metabolic improvements documented with SCFA changes observed.

PubMed ID: 34956218

Oat intervention reduced total/LDL cholesterol and increased SCFA‑related taxa—human RCT evidence that SCFA‑modulating diets improve metabolic biomarkers.

PubMed ID: 34996347

Probiotic increased circulating butyrate and correlated with HbA1c improvements in T2D—strong evidence linking butyrate increases to better metabolic control.

PubMed ID: 40577952

Oral butyrate improved muscle strength, gait speed and balance in older men — indicates functional metabolic improvements.

PubMed ID: 40565024

Sodium butyrate reduced serum TMAO (metabolic/CV marker) over time in MASLD patients—evidence for a metabolic effect.

PubMed ID: 40960896

Children in the Faecalibacterium‑dominated cluster lost adiposity with wholegrain intake and had tendencies toward favorable butyrate responses—suggests a microbiome‑butyrate link to metabolic outcomes.

PubMed ID: 41582618

Soy‑protein diet increased butyrate and showed modest muscle performance/IL‑6 improvements relevant to metabolic health.

PubMed ID: 32675291

Probiotic with butyrate producers improved postprandial glucose AUC and trended to lower A1c — metabolic improvement plausibly mediated via butyrate producers.

PubMed ID: 40371708

Anaerobutyricum RCT improved HbA1c slightly and reduced glucose variability and diastolic BP — metabolic benefits consistent with butyrate biology.

PubMed ID: 40669445

Chicory fiber increased fecal butyrate and significantly improved peripheral insulin sensitivity and non‑oxidative glucose disposal.

PubMed ID: 38684660

Synbiotic intervention improved HDL and altered miRNAs while increasing fecal butyrate, indicating metabolic effects.

PubMed ID: 39448815

Sodium butyrate increased PGC‑1α and UCP1 expression and improved weight/lipids/glycemia on a hypocaloric diet — direct metabolic benefit.

PubMed ID: 39064648

Dietary fiber/postbiotic supplement lowered HbA1c and fasting glucose and increased butyrate‑associated taxa in prediabetic adults—direct metabolic improvement linked to butyrate‑related microbiota changes.

PubMed ID: 39125336

12‑week calcium‑butyrate formula improved fatty liver index and lowered TC/TG/gGT in NAFLD patients—direct metabolic benefits consistent with better hepatic/ systemic metabolism.

PubMed ID: 39599737

Heat‑treated B. longum increased faecal butyrate and decreased total/non‑HDL cholesterol—supports modest metabolic benefit via microbiome modulation.

PubMed ID: 19224658

Low‑carb diet decreased stool weight and total faecal SCFA (including butyrate), showing that SCFA levels link to stool output and waste handling.

PubMed ID: 16469156

Lupin fibre increased stool output and sped transit and raised faecal butyrate — direct human evidence that bowel transit and waste removal improved (moderate‑strong indirect support for enhanced clearance mediated by SCFA production).

PubMed ID: 12641543

Improved bowel symptoms (movements, urgency) and mucosal healing in UC suggest improved colonic function and waste passage in affected patients.

PubMed ID: 12038477

Documented increase in fecal bulk and butyrate output—directly supports enhanced waste removal (stool bulk) and colonic fermentation as detox pathway.

PubMed ID: 9706795

Fermented oats increased stool volume and fecal SCFAs, indicating improved waste transit and removal.

PubMed ID: 31686768

Improved stool frequency and reduced serum LPS imply better intestinal waste clearance and lower translocation of microbial products.

PubMed ID: 41261535

Improved spontaneous bowel movements and increased fecal SCFAs suggest enhanced colonic transit and waste removal linked to butyrate‑producing taxa.

PubMed ID: 40421856

Endotoxin decreased alongside increased fecal butyrate in interventions — consistent with reduced systemic exposure to gut‑derived toxins.

PubMed ID: 40081693

LBP decreased with butyrate, implying reduced bacterial translocation/endotoxin burden and improved clearance of gut‑derived waste signals.

PubMed ID: 41233756

Inulin increased stool frequency (greater waste transit) and improved constipation‑related QoL, which supports enhanced waste removal.

PubMed ID: 40167641

Reduced zonulin and LBP after sodium butyrate imply less endotoxin translocation and improved gut containment of waste/toxins.

PubMed ID: 40286792

Improved bowel frequency and decreased straining indicate better waste removal; fecal butyrate was increased.

PubMed ID: 38931207

Symbiotic meal reduced certain uremic toxins (p‑cresyl sulfate, indole‑3‑acetic acid) while increasing stool butyrate — clear evidence for enhanced removal/ detoxification relevance.

PubMed ID: 38315140

Colon‑targeted rifamycin lowered venous ammonia and raised stool SCFAs including butyrate—direct evidence of improved removal/processing of gut‑derived toxins (ammonia).

PubMed ID: 39125336

Calcium‑butyrate improved gGT and fatty liver index—hepatic improvements suggest better hepatic detox/metabolic handling, though mechanism not isolated to butyrate.

PubMed ID: 37751049

Improved bowel function and increased butyrate correlate with more effective waste clearance and colon transit in constipated subjects.

PubMed ID: 37367942

Higher abundance of butyrate producer associated with fewer GI issues, implying better intestinal function and waste management.

PubMed ID: 36678227

Reduction in diarrhea and GI complications with increased fecal SCFAs suggests improved GI function and waste handling during chemotherapy.

PubMed ID: 36499011

Improved stool frequency/consistency after rhubarb implies enhanced waste elimination and increased fecal butyrate.

PubMed ID: 36055959

Improved gut barrier (lower LBP/zonulin) via increased SCFAs reduces bacterial translocation/endotoxin load — indirectly supporting detoxification and reduced systemic waste burden.

PubMed ID: 30716942

Direct evidence: synbiotic increased fecal butyrate and significantly decreased serum gut-derived uremic toxins (p‑CS and IS) and urea—strong support that modulating colonic fermentation reduced systemic gut-derived toxins in these patients.

PubMed ID: 20089780

Rye shortened transit time and increased defecation frequency — aids waste removal.

PubMed ID: 19480733

Sodium butyrate altered digestibility and faecal measures in piglets, implying effects on waste processing and nutrient extraction.

PubMed ID: 40274191

Inulin RCT increased microbial butyrate production and plasma/fecal SCFAs, which can support enterocyte energy and nutrient uptake.

PubMed ID: 36517799

Soluble prebiotic raised circulating butyrate and hemoglobin—suggests improved nutrient/utilization in HD patients.

PubMed ID: 38135194

Oral butyrate lowered plasma zonulin (intestinal permeability marker), implying improved barrier that can support nutrient absorption.

PubMed ID: 40167641

Oral sodium butyrate lowered zonulin (intestinal permeability marker), implying improved mucosal function and likely better nutrient uptake.

PubMed ID: 27065265

Swine feed study showed improved fiber/energy digestibility and higher cecal butyrate — directly links butyrate levels to nutrient digestibility.

PubMed ID: 26015588

Encapsulated butyric acid increased broiler growth and feed conversion, implying improved nutrient utilization/absorption in animals.

PubMed ID: 33829223

Genetic proxies for higher microbial butyrate production modified fiber-related gains in whole‑body BMD during weight‑loss, implying enhanced nutrient/mineral handling linked to butyrate biology.

PubMed ID: 11053512

Acarbose raised fecal butyrate and increased rectal crypt cell proliferation (BrdU), consistent with enhanced absorptive mucosa function.

PubMed ID: 19480733

Piglet study: pre‑weaning sodium butyrate improved post‑weaning feed digestibility—direct animal evidence for improved nutrient uptake.

PubMed ID: 23776267

Whole‑wheat diet in turkeys raised intestinal butyrate and improved feed efficiency, implying improved nutrient utilisation (animal model).

PubMed ID: 25207431

Butyric acid glycerides in broiler chickens reduced gut lesions and improved growth—indirect evidence of improved nutrient utilisation (animal model).

PubMed ID: 25726104

Sodium-butyrate in cows increased rumen papillae development and prepartum feed intake—anatomical/feeding changes consistent with improved absorptive capacity (animal model).

PubMed ID: 30634590

Phenylbutyrate+vitamin D sharply increased 25(OH)D levels in HIV patients, indicating improved vitamin D status (direct evidence of improved a nutrient level).

PubMed ID: 40751371

IBS symptom improvements correlated with higher fecal butyrate after FMT; bloating is a common IBS symptom and likely improved.

PubMed ID: 41233756

Constipation QoL improvements with inulin likely reflect reduced bloating and discomfort in constipated participants.

PubMed ID: 40635319

Pediatric oral butyrate sharply reduced abdominal pain and related symptoms; likely accompanied by reduced bloating.

PubMed ID: 40575487

IBS RCT with SCFA‑producing probiotic reduced global symptom scores (which include bloating) while increasing butyrate.

PubMed ID: 40286792

Constipation relief (more bowel movements, less straining) commonly reduces bloating; fecal butyrate rose.

PubMed ID: 39689011

taVNS improved IBS abdominal symptoms and increased fecal SCFAs including butyrate—consistent with reduced bloating.

PubMed ID: 24063909

Traveler RCT reported lower GI symptom scores including bloating with sodium butyrate/SCFA vs placebo (human RCT).

PubMed ID: 37751049

GOS improved constipation and QoL; reductions in bowel dysfunction often accompany less bloating (indirect).

PubMed ID: 36678227

Postop probiotic group reported less abdominal distention (bloating) during chemotherapy (statistically significant reduction).

PubMed ID: 36499011

Improved stool frequency/consistency after rhubarb could reduce bloating (clinical implication).

PubMed ID: 36717369

IBS‑D probiotic reduced diarrhea/bloating symptoms while increasing fecal butyrate—strong symptomatic link.

PubMed ID: 32433273

Low‑FODMAP arms reported improved IBS symptom relief (clinically meaningful reduction in symptoms that include bloating).

PubMed ID: 32945066

Increased fecal butyrate after FMT inversely correlated with IBS symptom severity (which includes bloating).

PubMed ID: 24343275

Patients with diverticulosis reported symptom relief with sodium butyrate, which commonly includes reduced abdominal discomfort/bloating.

PubMed ID: 30400947

Three days of rye/resistant-starch dinners increased plasma butyrate (~37%) and produced a modest but statistically significant improvement in insulin sensitivity (ISI_composite ~+11%).

PubMed ID: 28924143

High‑dose prebiotics lowered fecal butyrate and were associated with worsened OGTT AUC, implying butyrate supports glycemic control (inverse evidence).

PubMed ID: 28962046

Randomized human trial in type 2 diabetes: sodium butyrate (especially combined with inulin) raised GLP‑1 and modestly reduced fasting blood sugar (significant vs placebo).

PubMed ID: 2209320

Bezafibrate lowered blood glucose in type 2 diabetics — direct glucose effect but drug-based, not butyrate.

PubMed ID: 34996347

Probiotic RCT in T2D increased circulating butyrate (~27%) and correlated increases with improved HbA1c—direct clinical link to glycemic improvement.

PubMed ID: 32675291

RCT in T2D: a probiotic containing butyrate producers improved postprandial glucose AUC and trended to lower A1c — direct relevance to glycemic control.

PubMed ID: 40371708

Oral Anaerobutyricum (butyrate‑producer) RCT produced modest but significant improvements in HbA1c and glucose variability.

PubMed ID: 40669445

Chicory‑root fiber raised fecal butyrate and produced significant improvements in peripheral insulin sensitivity and non‑oxidative glucose disposal.

PubMed ID: 39448815

Oral sodium butyrate in people with obesity on calorie restriction lowered fasting glucose (FBS) and improved metabolic gene expression — direct glycemic benefit.

PubMed ID: 39064648

12‑week dietary‑fiber/postbiotic supplement lowered HbA1c and fasting glucose while enriching putative butyrate producers—direct glycemic improvement linked to increased butyrate‑associated taxa.

PubMed ID: 36594522

Randomized trial of a fibre‑enriched prebiotic raised butyrate‑producer abundance and produced a clinically meaningful HbA1c drop (−0.64%).

PubMed ID: 35833889

Replacing white rice with germinated brown rice raised stool SCFAs (incl. butyrate) and improved fasting glucose in T2D.

PubMed ID: 36469320

Oral sodium butyrate for 6 months in children with overweight/obesity significantly lowered BMI and HOMA‑IR, directly supporting better blood‑sugar balance from butyrate.

PubMed ID: 33671147

Short‑term replacement with RS2‑enriched wheat (linked to butyrate‑producer enrichment) lowered postprandial glucose and insulin iAUCs, suggesting butyrate‑related improvements in glycemic responses.

PubMed ID: 32660025

In metformin users, probiotic (raised plasma butyrate) lowered fasting glucose, HbA1c and HOMA‑IR — direct metabolic benefit.

PubMed ID: 35179758

Direct RCT of energy‑restricted diet in PCOS showed weight loss with simultaneous decreases in fecal butyrate—evidence that weight change relates to fecal SCFA dynamics (complex but directly relevant).

PubMed ID: 40960896

Wholegrain effects on adiposity were strongly modified by baseline Faecalibacterium (a butyrate producer); the Faecalibacterium‑dominated cluster lost fat and tended to have favorable butyrate responses.

PubMed ID: 40369689

Infant formula that promoted butyrate‑producing bacteria was associated with slightly lower BMI at 1 year.

PubMed ID: 40669445

Chicory fiber raised butyrate, reduced triglycerides and shifted adipocyte size toward smaller cells—supports metabolic/weight regulation.

PubMed ID: 39448815

Randomized trial: oral sodium butyrate (600 mg/d) with caloric restriction increased PGC‑1α/UCP1 expression and produced greater weight loss vs placebo — clear direct support.

PubMed ID: 39125336

Oral calcium‑butyrate formula improved fatty liver index and lowered TG/TC in NAFLD with metabolic syndrome—metabolic improvements relevant to weight management support.

PubMed ID: 35458231

Rye intake modestly raised plasma butyrate and correlated with greater weight/body-fat loss in an RCT—strongest direct link in this dataset.

PubMed ID: 36469320

Direct RCT of oral butyrate in pediatric overweight/obesity produced a clinically meaningful reduction in BMI versus placebo over 6 months.

PubMed ID: 34523948

Human study: short-term low‑carb diet produced significant weight loss and increased certain butyrate-producing gut bacteria — reasonably strong indirect evidence that butyrate-producing microbiota correlate with weight-change outcomes.

PubMed ID: 28962046

Butyrate (+/− inulin) groups showed modest reductions in waist circumference/waist-to-hip ratio in a small RCT, suggesting some support for central adiposity improvement.

PubMed ID: 38717445

Same study—strong evidence for mood benefits linked to increased systemic butyrate (listed twice reflecting strong relevance).

PubMed ID: 30400947

Three-day rye/resistant-starch intervention modestly improved mood alongside increased plasma SCFAs (including butyrate)—direct human evidence of a gut–brain signal.

PubMed ID: 34396468

Human RCT with cognitive/attention improvements paired with in vitro demonstration that the ginseng extract increased butyrate production—supports a connection between microbial SCFA production and cognitive performance (indirect but relevant).

PubMed ID: 38199487

Colon‑targeted butyrate raised serum butyrate and altered subjective fear memory in healthy men — direct behavioral/neuro effect.

PubMed ID: 39599626

Multispecies probiotic increased stool butyrate and reduced fatigue in post‑COVID patients—suggests mood/energy benefits possibly mediated by SCFAs.

PubMed ID: 37751049

GOS gummy improved mood and QoL measures while increasing butyrate — supports gut–brain relevance of SCFAs.

PubMed ID: 40670166

In MCI patients acupuncture increased abundance of butyrate‑producing bacteria and improved cognitive scores—an indirect but clinically observed gut‑brain association involving butyrate producers.

PubMed ID: 40751371

Long‑term FMT recipients had reductions in fatigue correlated with raised fecal butyrate, suggesting possible mood/energy benefits (indirect).

PubMed ID: 41350593

Randomized trial supplementing propionate+butyrate (with prebiotic) improved motor scores and medication needs in Parkinson's—central nervous system benefit linked to SCFAs.

PubMed ID: 36003050

Pediatric probiotic trial increased fecal butyrate and substantially improved eczema severity and caregiver QoL — direct skin benefit linked to SCFA increase.

PubMed ID: 39000417

Phenylalanine butyramide (a butyrate derivative) inhibited tyrosinase in vitro and in a 30‑day randomized study produced measurable skin lightening and improved firmness/elasticity — direct dermal evidence.

PubMed ID: 16965415

Topical mupirocin + hydrocortisone butyrate improved eczema and reduced S. aureus colonization—clear dermatologic benefit for a product named 'butyrate' (a steroid ester).

PubMed ID: 18380208

Hydrocortisone butyrate 0.1% lotion (the term 'butyrate' here refers to the steroid ester) improved atopic dermatitis in children — clear skin benefit, but this is a topical corticosteroid study, not dietary butyrate.

PubMed ID: 28866384

Strongest direct link in this set: infants who developed eczema had lower fecal butyrate and fewer butyrate-producers, implicating butyrate in skin/allergy outcomes.

PubMed ID: 41350593

Butyrate+propionate supplementation showed clinical CNS benefit in PD (motor improvement); cognitive/attention gains are plausible but not directly measured.

PubMed ID: 38717445

Probiotic‑induced plasma butyrate increases correlated with improved anxiety/depression scores and reduced amygdala reactivity—relevant to mood and cognitive‑affective processing.

PubMed ID: 34396468

Human trial of American ginseng (Cereboost®) improved attention measures; in vitro gut model showed increased butyrate production—supports a plausible microbiome→SCFA→cognition link.